<Summary id="CDR0000062945" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Small cell lung cancer treatment options include surgery, chemotherapy and radiation therapy, laser therapy, targeted therapy, and palliative care. Get detailed treatment information for newly diagnosed and recurrent small cell lung cancer in this summary for clinicians.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq">Small Cell Lung Cancer (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/lung/patient/small-cell-lung-treatment-pdq">Small Cell Lung Cancer (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028327">PDQ Adult Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000040962">small cell lung cancer</TermRef></MainTopics><SummaryAbstract><Para id="_369">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of small cell lung cancer. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_370">This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>small cell lung cancer</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Small Cell Lung Cancer Treatment (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Small Cell Lung Cancer Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000040962">small cell lung cancer</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Small Cell Lung Cancer (SCLC)</Title><Para id="_2">SCLC accounts for approximately 15% of bronchogenic carcinomas.</Para><Para id="_4">At the time of diagnosis, approximately 30% of patients with SCLC have tumors confined to the hemithorax of origin, mediastinum, or supraclavicular lymph nodes. These patients have limited-stage disease (LD).<Reference refidx="1"/> Patients with tumors that have spread beyond the supraclavicular areas have extensive-stage disease (ED).</Para><Para id="_194">SCLC is more responsive to chemotherapy and radiation therapy than other cell types of lung cancer. However, a cure is difficult to achieve because SCLC has a greater tendency to be widely disseminated by the time of diagnosis.</Para><SummarySection id="_6"><Title>Incidence and Mortality</Title><Para id="_7">The overall incidence and mortality rates of SCLC in the United States have decreased during the past few decades.<Reference refidx="2"/></Para><Para id="_8">Estimated new cases and deaths from lung cancer (SCLC and non-small cell lung cancer [NSCLC] combined) in the United States in 2025:<Reference refidx="3"/></Para><ItemizedList id="_9" Style="bullet">
     <ListItem>New cases: 226,650.</ListItem><ListItem>Deaths: 124,730.</ListItem></ItemizedList></SummarySection><SummarySection id="_376"><Title>Risk Factors</Title><SummarySection id="_sm_CDR0000752176_1"><SectMetaData><SpecificDiagnosis ref="CDR0000040209">lung cancer</SpecificDiagnosis><SectionType>Risk factors</SectionType></SectMetaData><Para id="_sm_CDR0000752176_4">Increasing age is the most important risk factor for most cancers. Other risk factors for lung cancer include:</Para><ItemizedList id="_sm_CDR0000752176_2" Style="bullet">
     <ListItem>History of or current tobacco use: cigarettes, pipes, and cigars.<Reference refidx="4"/></ListItem><ListItem>Exposure to cancer-causing substances in secondhand smoke.<Reference refidx="5"/><Reference refidx="6"/></ListItem><ListItem>Occupational exposure to asbestos, arsenic, chromium, beryllium, nickel, and other agents.<Reference refidx="7"/></ListItem><ListItem>Radiation exposure from  any of the following sources:<ItemizedList id="_sm_CDR0000752176_5" Style="dash">
     <ListItem>Radiation therapy to the breast or chest.<Reference refidx="8"/></ListItem><ListItem>Radon exposure in the home or workplace.<Reference refidx="9"/></ListItem><ListItem>Medical imaging tests, such as computed tomography (CT) scans.<Reference refidx="10"/></ListItem><ListItem>Atomic bomb radiation.<Reference refidx="11"/></ListItem></ItemizedList></ListItem><ListItem>Living in an area with air pollution.<Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/></ListItem><ListItem>Family history of lung cancer.<Reference refidx="15"/></ListItem><ListItem>HIV infection.<Reference refidx="16"/></ListItem><ListItem>Beta carotene supplements in heavy smokers.<Reference refidx="17"/><Reference refidx="18"/></ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_16"><Title>Clinical Features</Title><Para id="_253">Lung cancer may present with symptoms or be found incidentally on chest imaging. Symptoms and signs may result from the location of the primary local invasion or compression of adjacent thoracic structures, distant metastases, or paraneoplastic phenomena. The most common symptoms at presentation are worsening cough and dyspnea. Other presenting symptoms include:</Para><ItemizedList id="_254" Style="bullet"><ListItem>Chest pain.</ListItem><ListItem>Hoarseness.</ListItem><ListItem>Malaise.</ListItem><ListItem>Anorexia.</ListItem><ListItem>Weight loss.</ListItem><ListItem>Hemoptysis.</ListItem></ItemizedList><Para id="_255">Symptoms may result from local invasion or compression of adjacent thoracic structures, such as compression involving the esophagus causing dysphagia, compression involving the laryngeal nerves causing hoarseness, or compression involving the superior vena cava causing facial edema and distension of the superficial veins of the head and neck. Symptoms from distant metastases may also be present and include neurological defects or personality changes from brain metastases and pain from bone metastases.</Para><Para id="_256">Infrequently, patients with SCLC may present with symptoms and signs of one of the following paraneoplastic syndromes:</Para><ItemizedList id="_257" Style="bullet"><ListItem>Inappropriate antidiuretic hormone secretion.</ListItem><ListItem>Cushing syndrome from secretion of adrenocorticotropic hormone.</ListItem><ListItem>Paraneoplastic cerebellar degeneration.</ListItem><ListItem>Lambert-Eaton myasthenic syndrome.<Reference refidx="2"/></ListItem></ItemizedList><Para id="_258">Physical examination may identify enlarged supraclavicular lymphadenopathy, pleural effusion or lobar collapse, unresolved pneumonia, or signs of associated disease such as chronic obstructive pulmonary disease.</Para></SummarySection><SummarySection id="_18"><Title>Diagnosis</Title><Para id="_259">Treatment options for patients are determined by histology, stage, and general health and comorbidities of the patient. Investigations of patients with suspected SCLC focus on confirming the diagnosis and determining the extent of the disease.</Para><Para id="_260">The procedures used to determine the presence of cancer include:</Para><ItemizedList id="_261" Style="bullet"><ListItem>History.</ListItem><ListItem>Physical examination.</ListItem><ListItem>Routine laboratory evaluations.</ListItem><ListItem>Chest x-ray.</ListItem><ListItem>Chest CT  scan with infusion of contrast material.</ListItem><ListItem>Biopsy.</ListItem></ItemizedList><Para id="_262">Before a patient begins lung cancer treatment, an experienced lung cancer pathologist must review the pathological material. This is critical because SCLC, which responds well to chemotherapy and is generally not treated surgically, can be confused on microscopic examination with NSCLC.<Reference refidx="19"/> Immunohistochemistry and electron microscopy are invaluable techniques for diagnosis and subclassification, but most lung tumors can be classified by light microscopic criteria.</Para><Para id="_263">For more information, see the <SummaryRef href="CDR0000062945#_50" url="/types/lung/hp/small-cell-lung-treatment-pdq">Staging Evaluation</SummaryRef> section.</Para></SummarySection><SummarySection id="_25"><Title>Prognosis and Survival</Title><Para id="_28">Regardless of stage, the prognosis for patients with SCLC is 	unsatisfactory despite improvements in diagnosis and therapy during the 	past 25 years. Without treatment, SCLC has the most aggressive clinical course of any type of pulmonary tumor, with a median survival from diagnosis of only 2 to 4 months. About 10% of people with SCLC remain free of disease during the 2 years from the start of therapy, which is the time period during which most relapses occur. However, even these patients are at risk of dying of lung cancer (both small and non-small cell types).<Reference refidx="20"/> The overall survival rate at 5 years is 5% to 10%.<Reference refidx="1"/><Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/> </Para><Para id="_234">An important prognostic factor for SCLC is the extent of disease. Patients with LD have a better prognosis than patients with ED. For patients with LD, the median survival is 16 to 24 months and the 5-year survival rates is 14% with current forms of treatment.<Reference refidx="1"/><Reference refidx="21"/><Reference refidx="23"/><Reference refidx="24"/> Patients diagnosed with LD who smoke should be encouraged to stop smoking before undergoing combined-modality therapy because continued smoking may compromise survival.<Reference refidx="25"/></Para><Para id="_32">Patients with LD have improved long-term survival with combined-modality therapy.<Reference refidx="24"/><Reference refidx="26"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] Although long-term survivors have 	been reported among patients who received either surgery or chemotherapy 	alone, chemotherapy combined with thoracic radiation therapy (TRT) is 	considered the standard of care.<Reference refidx="27"/> Adding TRT increases absolute survival by 	approximately 5% over chemotherapy alone.<Reference refidx="26"/><Reference refidx="28"/> Multiple trials and meta-analyses have evaluated the optimal timing of TRT 	relative to chemotherapy, 	with the weight of evidence suggesting a small benefit to early TRT.<Reference refidx="1"/><Reference refidx="29"/><Reference refidx="30"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</Para><Para id="_33">In patients with ED, the median survival  6 to 	12 months with currently available therapy, but long-term disease-free 	survival is rare.</Para><Para id="_195">Prophylactic cranial radiation prevents central nervous system recurrence and can improve survival in patients with good performance status who have had a complete response or a very good partial response to chemoradiation in LD or chemotherapy in ED.<Reference refidx="31"/><Reference refidx="32"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] </Para><Para id="_307">Thoracic radiation may also improve long-term outcomes for these patients.<Reference refidx="33"/></Para><Para id="_196">All patients with this type of cancer may appropriately be considered for inclusion in clinical trials at the time of diagnosis. Information about ongoing clinical trials is available from the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/disease/small-cell-lung-cancer">NCI website</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8381164" MedlineID="93147868">Murray N, Coy P, Pater JL, et al.: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11 (2): 336-44, 1993.</Citation><Citation idx="2" PMID="17008692">Govindan R, Page N, Morgensztern D, et al.: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24 (28): 4539-44, 2006.</Citation><Citation idx="3">American Cancer Society: Cancer Facts and Figures 2025. American Cancer Society, 2025. <ExternalRef xref="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf">Available online</ExternalRef>. Last accessed January 16, 2025.</Citation><Citation idx="4" PMID="17873159">Alberg AJ, Ford JG, Samet JM, et al.: Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 (3 Suppl): 29S-55S, 2007.</Citation><Citation idx="5" PMID="15894687">Tulunay OE, Hecht SS, Carmella SG, et al.: Urinary metabolites of a tobacco-specific lung carcinogen in nonsmoking hospitality workers. Cancer Epidemiol Biomarkers Prev 14 (5): 1283-6, 2005.</Citation><Citation idx="6" PMID="14693752">Anderson KE, Kliris J, Murphy L, et al.: Metabolites of a tobacco-specific lung carcinogen in nonsmoking casino patrons. Cancer Epidemiol Biomarkers Prev 12 (12): 1544-6, 2003.</Citation><Citation idx="7" PMID="19418618">Straif K, Benbrahim-Tallaa L, Baan R, et al.: A review of human carcinogens--part C: metals, arsenic, dusts, and fibres. Lancet Oncol 10 (5): 453-4, 2009.</Citation><Citation idx="8" PMID="20634481">Friedman DL, Whitton J, Leisenring W, et al.: Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 102 (14): 1083-95, 2010.</Citation><Citation idx="9" PMID="19129153">Gray A, Read S, McGale P, et al.: Lung cancer deaths from indoor radon and the cost effectiveness and potential of policies to reduce them. BMJ 338: a3110, 2009.</Citation><Citation idx="10" PMID="18927099">Berrington de González A, Kim KP, Berg CD: Low-dose lung computed tomography screening before age 55: estimates of the mortality reduction required to outweigh the radiation-induced cancer risk. J Med Screen 15 (3): 153-8, 2008.</Citation><Citation idx="11" PMID="2305030">Shimizu Y, Kato H, Schull WJ: Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 2. Cancer mortality based on the recently revised doses (DS86). Radiat Res 121 (2): 120-41, 1990.</Citation><Citation idx="12" PMID="21325732">Katanoda K, Sobue T, Satoh H, et al.: An association between long-term exposure to ambient air pollution and mortality from lung cancer and respiratory diseases in Japan. J Epidemiol 21 (2): 132-43, 2011.</Citation><Citation idx="13" PMID="21194838">Cao J, Yang C, Li J, et al.: Association between long-term exposure to outdoor air pollution and mortality in China: a cohort study. J Hazard Mater 186 (2-3): 1594-600, 2011.</Citation><Citation idx="14" PMID="20966448">Hales S, Blakely T, Woodward A: Air pollution and mortality in New Zealand: cohort study. J Epidemiol Community Health 66 (5): 468-73, 2012.</Citation><Citation idx="15" PMID="20306329">Lissowska J, Foretova L, Dabek J, et al.: Family history and lung cancer risk: international multicentre case-control study in Eastern and Central Europe and meta-analyses. Cancer Causes Control 21 (7): 1091-104, 2010.</Citation><Citation idx="16" PMID="19770804">Shiels MS, Cole SR, Kirk GD, et al.: A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52 (5): 611-22, 2009.</Citation><Citation idx="17" PMID="8127329" MedlineID="94173292">The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330 (15): 1029-35, 1994.</Citation><Citation idx="18" PMID="8602180" MedlineID="96185731">Omenn GS, Goodman GE, Thornquist MD, et al.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334 (18): 1150-5, 1996.</Citation><Citation idx="19">Travis WD, Colby TV, Corrin B, et al.: Histological typing of lung and pleural tumours. 3rd ed. Springer-Verlag, 1999.</Citation><Citation idx="20" PMID="2155310" MedlineID="90172011">Johnson BE, Grayson J, Makuch RW, et al.: Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J Clin Oncol 8 (3): 396-401, 1990.</Citation><Citation idx="21" PMID="8646697" MedlineID="96208595">Fry WA, Menck HR, Winchester DP: The National Cancer Data Base report on lung cancer. Cancer 77 (9): 1947-55, 1996.</Citation><Citation idx="22" PMID="7738624" MedlineID="95256945">Lassen U, Osterlind K, Hansen M, et al.: Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients. J Clin Oncol 13 (5): 1215-20, 1995.</Citation><Citation idx="23" PMID="9920950" MedlineID="99110542">Turrisi AT, Kim K, Blum R, et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 (4): 265-71, 1999.</Citation><Citation idx="24" PMID="12237922">Jänne PA, Freidlin B, Saxman S, et al.: Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 95 (7): 1528-38, 2002.</Citation><Citation idx="25" PMID="12697879">Videtic GM, Stitt LW, Dar AR, et al.: Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 21 (8): 1544-9, 2003.</Citation><Citation idx="26" PMID="1331787" MedlineID="93063085">Pignon JP, Arriagada R, Ihde DC, et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327 (23): 1618-24, 1992.</Citation><Citation idx="27" PMID="16706259">Chandra V, Allen MS, Nichols FC, et al.: The role of pulmonary resection in small cell lung cancer. Mayo Clin Proc 81 (5): 619-24, 2006.</Citation><Citation idx="28" PMID="1316951" MedlineID="92268942">Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10 (6): 890-5, 1992.</Citation><Citation idx="29" PMID="3029592" MedlineID="87144519">Perry MC, Eaton WL, Propert KJ, et al.: Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316 (15): 912-8, 1987.</Citation><Citation idx="30" PMID="12118018">Takada M, Fukuoka M, Kawahara M, et al.: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20 (14): 3054-60, 2002.</Citation><Citation idx="31" PMID="10441603" MedlineID="99353503">Aupérin A, Arriagada R, Pignon JP, et al.: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341 (7): 476-84, 1999.</Citation><Citation idx="32" PMID="17699816">Slotman B, Faivre-Finn C, Kramer G, et al.: Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357 (7): 664-72, 2007.</Citation><Citation idx="33" PMID="25230595">Slotman BJ, van Tinteren H, Praag JO, et al.: Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 385 (9962): 36-42, 2015.</Citation></ReferenceSection></SummarySection><SummarySection id="_275"><SectMetaData><SpecificDiagnosis ref="CDR0000040962">small cell lung cancer</SpecificDiagnosis><SectionType>Cellular classification--legacy</SectionType></SectMetaData><Title>Cellular Classification of SCLC</Title><Para id="_38">Before initiating treatment for a patient with small cell lung cancer (SCLC), an experienced lung cancer pathologist should review the pathological material.</Para><SummarySection id="_39"><Title>Pathological Classification</Title><Para id="_40">The current classification of subtypes of SCLC includes:<Reference refidx="1"/></Para><ItemizedList id="_41" Style="bullet">
     <ListItem>Small cell carcinoma.</ListItem><ListItem>Combined small cell carcinoma (i.e., SCLC combined with additional components from any of the non-small cell lung carcinoma histological types).</ListItem></ItemizedList><Para id="_42">SCLC arising from neuroendocrine cells forms one extreme of the spectrum of neuroendocrine carcinomas of the lung.</Para><Para id="_43">Neuroendocrine tumors include:</Para><ItemizedList id="_44" Style="bullet">
     <ListItem>Low-grade typical carcinoid.</ListItem><ListItem>Intermediate-grade atypical carcinoid.</ListItem><ListItem>High-grade neuroendocrine tumors, including large-cell neuroendocrine carcinoma (LCNEC) and SCLC.</ListItem></ItemizedList><Para id="_45">Because of differences in clinical behavior, therapy, and epidemiology, these tumors are classified separately in the World Health Organization (WHO) revised classification. The variant form of SCLC called mixed small cell/large cell carcinoma was not retained in the revised WHO classification. Instead, SCLC is now divided into SCLC and combined SCLC.<Reference refidx="2"/>  No minimum percentage of the additional component is required for a combined SCLC diagnosis with the exception of mixed LCNEC and SCLC, in which a 10% minimum LCNEC component is required.<Reference refidx="3"/></Para><Para id="_46">SCLC presents as a proliferation of small cells with the following morphological features:<Reference refidx="4"/></Para><ItemizedList id="_47" Style="bullet">
     <ListItem>Scant cytoplasm.</ListItem><ListItem>Ill-defined borders.</ListItem><ListItem>Finely granular <Emphasis>salt and pepper</Emphasis> chromatin.</ListItem><ListItem>Absent or inconspicuous nucleoli.</ListItem><ListItem>Frequent nuclear molding.</ListItem><ListItem>A high mitotic count.</ListItem></ItemizedList><Para id="_197">Nearly all SCLC are immunoreactive for keratin, thyroid transcription factor 1, and epithelial membrane antigen. Neuroendocrine and neural differentiation result in the expression of dopa decarboxylase, calcitonin, neuron-specific enolase, chromogranin A, CD56 (also known as nucleosomal histone kinase 1 or neural-cell adhesion molecule), gastrin-releasing peptide, and insulin-like growth factor 1. One or more markers of neuroendocrine differentiation can be found in approximately 75% of SCLC.<Reference refidx="5"/></Para><Para id="_198">Although preinvasive and <Emphasis>in situ</Emphasis> malignant changes are frequently found in patients with non-small cell lung cancer, these findings are rare in patients with SCLC.<Reference refidx="6"/></Para></SummarySection><ReferenceSection><Citation idx="1">Travis WD, Colby TV, Corrin B, et al.: Histological typing of lung and pleural tumours. 3rd ed. Springer-Verlag, 1999.</Citation><Citation idx="2" PMID="32592985">Lei Y, Feng H, Qiang H, et al.: Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study. Lung Cancer 146: 244-251, 2020.</Citation><Citation idx="3" PMID="34952268">Simbolo M, Centonze G, Ali G, et al.: Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities. ESMO Open 7 (1): 100308, 2022.</Citation><Citation idx="4" PMID="11829087">Brambilla E, Travis WD, Colby TV, et al.: The new World Health Organization classification of lung tumours. Eur Respir J 18 (6): 1059-68, 2001.</Citation><Citation idx="5" PMID="7524299">Guinee DG, Fishback NF, Koss MN, et al.: The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol 102 (4): 406-14, 1994.</Citation><Citation idx="6">Kumar V, Abbas A, Fausto N, eds.: Robins and Cotran Pathologic Basis of Disease. 7th ed. Elsevier Inc, 2005.</Citation></ReferenceSection></SummarySection><SummarySection id="_37"><SectMetaData><SpecificDiagnosis ref="CDR0000040962">small cell lung cancer</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for SCLC</Title><SummarySection id="_264"><Title>Staging Systems</Title><Para id="_265">Several staging systems have been proposed for small cell lung cancer (SCLC).</Para><ItemizedList id="_266" Style="bullet"><ListItem>American Joint Committee on Cancer (AJCC) Tumor, Node, and  Metastasis (TNM).<Reference refidx="1"/> The 8th edition of the <Emphasis>AJCC Cancer Staging Manual</Emphasis> recommends the use of the TNM to classify SCLC. For more information, see the <SummaryRef href="CDR0000062932#_510" url="/types/lung/hp/non-small-cell-lung-treatment-pdq">AJCC Stage Groupings and TNM Definitions</SummaryRef> section in Non-Small Cell Lung Cancer Treatment.</ListItem><ListItem>Veterans Administration Lung Study Group (VALG).<Reference refidx="2"/></ListItem><ListItem>International Association for the Study of Lung Cancer (IASLC).<Reference refidx="3"/></ListItem></ItemizedList></SummarySection><SummarySection id="_267"><Title>Limited-Stage Disease</Title><Para id="_268">No universally accepted definition of this term is available. Limited-stage disease (LD) SCLC is confined to the hemithorax of origin, mediastinum, or supraclavicular nodes, which can be encompassed within a tolerable radiation therapy port. </Para><Para id="_269">Patients with pleural effusion, massive pulmonary tumor, and contralateral supraclavicular nodes have been both included in and excluded from LD by various groups. </Para></SummarySection><SummarySection id="_270"><Title>Extensive-Stage Disease</Title><Para id="_271">Extensive-stage disease (ED) SCLC has spread beyond the supraclavicular areas and is too widespread to be included within the definition of LD. Patients with distant metastases (M1) are always considered to have ED.<Reference refidx="3"/><Reference refidx="4"/></Para></SummarySection><SummarySection id="_272"><Title>IASLC-AJCC TNM Staging System</Title><Para id="_273">The AJCC TNM defines LD as any T, except for T3–4, due to multiple lung nodules that do not fit in a tolerable radiation field, any N, and  M0.<Reference refidx="1"/>  This corresponds to TNM stages I to IIIB.  Extensive disease is TNM stage IV with distant metastases (M1), including malignant pleural effusions.<Reference refidx="3"/><Reference refidx="4"/> For more information, see the <SummaryRef href="CDR0000062932#_510" url="/types/lung/hp/non-small-cell-lung-treatment-pdq">AJCC Stage Groupings and TNM Definitions</SummaryRef> section in Non-Small Cell Lung Cancer Treatment.</Para><Para id="_274">
        The IASLC conducted an analysis of clinical TNM staging for SCLC using the sixth edition of the AJCC TNM staging system for lung cancer. Survival rates for patients with clinical stages I and II disease are significantly different from those for patients with stage III disease with N2 or N3 involvement.<Reference refidx="3"/> Patients with pleural effusion have an intermediate prognosis between LD and ED with hematogenous metastases and will be classified as having M1 disease (or ED). Application of the TNM system will not change how patients are managed; however, the analysis suggests that, in the context of clinical trials in LD, accurate TNM staging and stratification may be important.<Reference refidx="3"/></Para></SummarySection><SummarySection id="_50"><Title>Staging Evaluation</Title><Para id="_51">Staging procedures for SCLC are important to distinguish patients with disease limited to their thorax from those with distant metastases. At the time of initial diagnosis, approximately two-thirds of patients with SCLC have clinical evidence of metastases; most of the remaining patients have clinical evidence of extensive nodal involvement in the hilar, mediastinal, and sometimes supraclavicular regions.</Para><Para id="_199">Determining the stage of cancer allows an assessment of prognosis and a determination of treatment, particularly when chest radiation therapy or surgical excision is added to chemotherapy for patients with LD. If ED is confirmed, further evaluation should be individualized according to the signs and symptoms unique to the individual patient. Standard staging procedures include:</Para><ItemizedList id="_52" Style="bullet">
     <ListItem>A thorough physical examination.</ListItem><ListItem>Routine blood counts and serum chemistries.</ListItem><ListItem>Chest and upper abdominal computed tomography (CT) scanning.</ListItem><ListItem>A radionuclide bone scan.</ListItem><ListItem>A brain magnetic resonance imaging scan or CT scan.</ListItem><ListItem>Bone marrow aspirate or biopsy in selected patients in which treatment would change based on the results.</ListItem></ItemizedList><Para id="_53">The role of positron emission tomography (PET) is still under study. SCLC is  fluorine F 18-fludeoxyglucose (18F-FDG) avid at the primary site and at metastatic sites. PET may be used in staging patients with SCLC who are potential candidates for the addition of thoracic radiation therapy to chemotherapy, as PET may lead to upstaging or downstaging of patients and to alteration of radiation fields resulting from the identification of additional sites of nodal metastases.</Para><Para id="_200">Evidence (18F-FDG PET):</Para><OrderedList id="_201" Style="Arabic">
     <ListItem>In a study of 120 patients with LD SCLC or ED SCLC, FDG-PET led to restaging of ten patients to a higher stage and three patients to a lower stage.<Reference refidx="5"/> FDG-PET was more sensitive and specific than CT scans for nonbrain distant metastases.</ListItem><ListItem>In a small series of 24 patients with LD by conventional staging, two patients were restaged to ED.<Reference refidx="2"/> Unsuspected nodal metastases were documented in 25% of patients, which altered the radiation plan in these patients. At this time, sensitivity, specificity, and positive- or negative-predictive value of PET scanning and its enhancement of staging accuracy are uncertain.</ListItem></OrderedList></SummarySection><ReferenceSection><Citation idx="1">Lung. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp. 431–56.</Citation><Citation idx="2" PMID="15310768">Bradley JD, Dehdashti F, Mintun MA, et al.: Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 22 (16): 3248-54, 2004.</Citation><Citation idx="3" PMID="18090577">Shepherd FA, Crowley J, Van Houtte P, et al.: The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2 (12): 1067-77, 2007.</Citation><Citation idx="4" PMID="9213298" MedlineID="97356862">Ihde D, Souhami B, Comis R, et al.: Small cell lung cancer. Lung Cancer 17 (Suppl 1): S19-21, 1997.</Citation><Citation idx="5" PMID="15258700">Brink I, Schumacher T, Mix M, et al.: Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 31 (12): 1614-20, 2004.</Citation></ReferenceSection></SummarySection><SummarySection id="_72"><SectMetaData><SpecificDiagnosis ref="CDR0000040962">small cell lung cancer</SpecificDiagnosis><SectionType>Treatment option overview--legacy</SectionType></SectMetaData><Title>Treatment Option Overview for SCLC</Title><Para id="_204">Chemotherapy and radiation therapy have been shown to improve survival for patients with small cell lung cancer (SCLC).</Para><SummarySection id="_75"><Title>Chemotherapy</Title><Para id="_76">Chemotherapy improves the survival of patients with limited-stage disease (LD) or extensive-stage disease (ED), but it is curative in only a few patients.<Reference refidx="1"/><Reference refidx="2"/> Because patients with SCLC tend to develop distant metastases, localized forms of treatment, such as surgical resection or radiation therapy, rarely produce long-term survival.<Reference refidx="3"/> Incorporating current chemotherapy regimens into the treatment program prolongs survival, with at least a fourfold to fivefold improvement in median survival compared with patients who are given no therapy. 
</Para><Para id="_78">The combination of platinum and etoposide is the most widely used standard chemotherapeutic regimen.<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] No consistent survival benefit has resulted from platinum versus nonplatinum combinations, increased dose intensity or dose density, altered mode of administration (e.g., alternating or sequential administration) of various chemotherapeutic agents, or maintenance chemotherapy.<Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</Para></SummarySection><SummarySection id="_79"><Title>Radiation Therapy</Title><Para id="_80">SCLC is highly radiosensitive and thoracic radiation therapy improves survival of patients with LD and ED tumors.<Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] Prophylactic cranial irradiation prevents central nervous system recurrence and may improve the long-term survival of patients with good performance status who have responded to chemoradiation therapy.<Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] This type of irradiation also offers palliation of symptomatic metastatic disease.</Para></SummarySection><Para id="_73">Treatment options for patients with LD, ED, or recurrent SCLC are summarized in <SummaryRef href="CDR0000062945#_74" url="/types/lung/hp/small-cell-lung-treatment-pdq">Table 1</SummaryRef>.</Para><Table id="_74"><Title>Table 1.  Treatment Options for Patients With SCLC</Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="44.24%"/><ColSpec ColName="col2" ColNum="2" ColWidth="55.75%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Center">Treatment Options</entry></Row></THead><TFoot><Row><entry NameEnd="col2" NameSt="col1">ED = extensive-stage disease; LD = limited-stage disease.</entry></Row></TFoot><TBody><Row><entry MoreRows="5"><SummaryRef href="CDR0000062945#_267" url="/types/lung/hp/small-cell-lung-treatment-pdq">LD</SummaryRef></entry><entry><SummaryRef href="CDR0000062945#_87" url="/types/lung/hp/small-cell-lung-treatment-pdq">Chemotherapy and radiation therapy</SummaryRef>
</entry></Row><Row><entry><SummaryRef href="CDR0000062945#_485515" url="/types/lung/hp/small-cell-lung-treatment-pdq">Adjuvant treatment after chemoradiation therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062945#_108" url="/types/lung/hp/small-cell-lung-treatment-pdq">Combination chemotherapy alone</SummaryRef>

</entry></Row><Row><entry><SummaryRef href="CDR0000062945#_110" url="/types/lung/hp/small-cell-lung-treatment-pdq">Surgery followed by chemotherapy or chemoradiation therapy</SummaryRef>
</entry></Row><Row><entry><SummaryRef href="CDR0000062945#_114" url="/types/lung/hp/small-cell-lung-treatment-pdq">Prophylactic cranial irradiation</SummaryRef></entry></Row><Row><entry>Clinical trials evaluating new drug regimens, surgical resection of the primary tumor, or new radiation therapy schedules and techniques (e.g., timing, three-dimensional treatment planning, and dose fractionation)</entry></Row><Row><entry MoreRows="3"><SummaryRef href="CDR0000062945#_270" url="/types/lung/hp/small-cell-lung-treatment-pdq">ED</SummaryRef></entry><entry><SummaryRef href="CDR0000062945#_485448" url="/types/lung/hp/small-cell-lung-treatment-pdq">Immune checkpoint modulation and combination chemotherapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062945#_127" url="/types/lung/hp/small-cell-lung-treatment-pdq">Combination chemotherapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062945#_155" url="/types/lung/hp/small-cell-lung-treatment-pdq">Radiation therapy</SummaryRef></entry></Row><Row><entry>Clinical trials evaluating new drug regimens or alternative drug doses and schedules</entry></Row><Row><entry MoreRows="4">Recurrent disease</entry><entry><SummaryRef href="CDR0000062945#_172" url="/types/lung/hp/small-cell-lung-treatment-pdq">Chemotherapy</SummaryRef>

</entry></Row><Row><entry><SummaryRef href="CDR0000062945#_485500" url="/types/lung/hp/small-cell-lung-treatment-pdq">Immunotherapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062945#_514" url="/types/lung/hp/small-cell-lung-treatment-pdq">Immune checkpoint modulation</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062945#_182" url="/types/lung/hp/small-cell-lung-treatment-pdq">Palliative therapy</SummaryRef></entry></Row><Row><entry>Phase I and II clinical trials evaluating new drugs</entry></Row></TBody></TGroup></Table><Para id="_81">Despite treatment advances, most patients with SCLC die of their tumor even with the best available therapy. Most of the improvements in survival of patients with SCLC are attributable to clinical trials that have attempted to improve on the best available and most accepted therapy. Patient entry into such studies is highly desirable.</Para><Para id="_82">Information about ongoing clinical trials is available from the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI website</ExternalRef>.</Para><ReferenceSection><Citation idx="1" PMID="9516611" MedlineID="98177254">Comis RL, Friedland DM, Good BC: Small-cell lung cancer: a perspective on the past and a preview of the future. Oncology (Huntingt) 12 (1 Suppl 2): 44-50, 1998.</Citation><Citation idx="2" PMID="14583943">Agra Y, Pelayo M, Sacristan M, et al.: Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev  (4): CD001990, 2003.</Citation><Citation idx="3" PMID="2556806" MedlineID="90085087">Prasad US, Naylor AR, Walker WS, et al.: Long term survival after pulmonary resection for small cell carcinoma of the lung. Thorax 44 (10): 784-7, 1989.</Citation><Citation idx="4" PMID="2155310" MedlineID="90172011">Johnson BE, Grayson J, Makuch RW, et al.: Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J Clin Oncol 8 (3): 396-401, 1990.</Citation><Citation idx="5" PMID="7738624" MedlineID="95256945">Lassen U, Osterlind K, Hansen M, et al.: Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients. J Clin Oncol 13 (5): 1215-20, 1995.</Citation><Citation idx="6" PMID="8646697" MedlineID="96208595">Fry WA, Menck HR, Winchester DP: The National Cancer Data Base report on lung cancer. Cancer 77 (9): 1947-55, 1996.</Citation><Citation idx="7" PMID="7931470" MedlineID="95016864">Ihde DC, Mulshine JL, Kramer BS, et al.: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12 (10): 2022-34, 1994.</Citation><Citation idx="8" PMID="8247036" MedlineID="94067212">Arriagada R, Le Chevalier T, Pignon JP, et al.: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 329 (25): 1848-52, 1993.</Citation><Citation idx="9" PMID="1847968" MedlineID="91154855">Klasa RJ, Murray N, Coldman AJ: Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 9 (3): 499-508, 1991.</Citation><Citation idx="10" PMID="8384264" MedlineID="93204187">Elias AD, Ayash L, Frei E, et al.: Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst 85 (7): 559-66, 1993.</Citation><Citation idx="11" PMID="10561291" MedlineID="20030020">Murray N, Livingston RB, Shepherd FA, et al.: Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17 (8): 2300-8, 1999.</Citation><Citation idx="12" PMID="18843733">Amarasena IU, Walters JA, Wood-Baker R, et al.: Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev  (4): CD006849, 2008.</Citation><Citation idx="13" PMID="1331787" MedlineID="93063085">Pignon JP, Arriagada R, Ihde DC, et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327 (23): 1618-24, 1992.</Citation><Citation idx="14" PMID="1316951" MedlineID="92268942">Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10 (6): 890-5, 1992.</Citation><Citation idx="15" PMID="8381164" MedlineID="93147868">Murray N, Coy P, Pater JL, et al.: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11 (2): 336-44, 1993.</Citation><Citation idx="16" PMID="25230595">Slotman BJ, van Tinteren H, Praag JO, et al.: Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 385 (9962): 36-42, 2015.</Citation><Citation idx="17" PMID="2175739" MedlineID="91086160">Turrisi AT, Glover DJ: Thoracic radiotherapy variables: influence on local control in small cell lung cancer limited disease. Int J Radiat Oncol Biol Phys 19 (6): 1473-9, 1990.</Citation><Citation idx="18" PMID="10441603" MedlineID="99353503">Aupérin A, Arriagada R, Pignon JP, et al.: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341 (7): 476-84, 1999.</Citation><Citation idx="19" PMID="17699816">Slotman B, Faivre-Finn C, Kramer G, et al.: Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357 (7): 664-72, 2007.</Citation></ReferenceSection></SummarySection><SummarySection id="_83"><SectMetaData><SpecificDiagnosis ref="CDR0000037819">limited stage small cell lung cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Limited-Stage SCLC</Title><SummarySection id="_86"><Title>Treatment Options for Patients With Limited-Stage SCLC</Title><Para id="_236">Treatment options for patients with <SummaryRef href="CDR0000062945#_267" url="/types/lung/hp/small-cell-lung-treatment-pdq">limited-stage small cell lung cancer (SCLC)</SummaryRef> include:</Para><OrderedList id="_85" Style="Arabic">
     <ListItem><SummaryRef href="CDR0000062945#_87" url="/types/lung/hp/small-cell-lung-treatment-pdq">Chemotherapy and radiation therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062945#_485515" url="/types/lung/hp/small-cell-lung-treatment-pdq">Adjuvant treatment after chemoradiation therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062945#_108" url="/types/lung/hp/small-cell-lung-treatment-pdq">Combination chemotherapy alone</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062945#_110" url="/types/lung/hp/small-cell-lung-treatment-pdq">Surgery followed by chemotherapy or chemoradiation therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062945#_114" url="/types/lung/hp/small-cell-lung-treatment-pdq">Prophylactic cranial irradiation (PCI)</SummaryRef>.</ListItem><ListItem>Clinical trials evaluating new drug regimens, surgical resection of the primary tumor, or new radiation therapy schedules and techniques (e.g., timing, three-dimensional treatment planning, and dose fractionation).</ListItem></OrderedList><SummarySection id="_87"><Title>Chemotherapy and radiation therapy</Title><Para id="_88">Combined-modality treatment with etoposide and cisplatin with thoracic radiation therapy (TRT) is the most widely used treatment for patients with limited-stage disease (LD) SCLC.</Para><Para id="_315">Evidence (combined-modality treatment):</Para><OrderedList id="_316" Style="Arabic">
     <ListItem><Strong>Survival.</Strong> The following results have been reported in clinical trials:<OrderedList id="_338" Style="LAlpha">
     <ListItem>Mature results of prospective randomized trials suggest that combined-modality therapy produces a modest but significant improvement in survival of 5% at 3 years compared with chemotherapy alone.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem><ListItem>Clinical trials have consistently achieved median survivals of 18 to 24 months and 2-year survival rates of 40% to 50%, with a treatment-related mortality rate of less than 3%.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem><ListItem>No consistent survival benefit has resulted from the following treatment approaches:<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/><ItemizedList id="_318" Style="bullet">
     <ListItem>Increased dose intensity.</ListItem><ListItem>Increased dose density.</ListItem><ListItem>Administration of additional drugs or other (non–etoposide-containing) platinum-based combination regimens.</ListItem><ListItem>Altered modes of administration of various chemotherapeutic agents.</ListItem><ListItem>Maintenance chemotherapy.</ListItem></ItemizedList></ListItem></OrderedList></ListItem><ListItem><Strong>Length of treatment.</Strong> The optimal duration of chemotherapy for patients with LD SCLC is not clearly defined, but no improvement exists in survival after the duration of drug administration exceeds 3 to 6 months. The preponderance of evidence available from randomized trials indicates that maintenance chemotherapy does not prolong survival for patients with LD SCLC.<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem><ListItem><Strong>Dose and timing.</Strong> The optimal dose and timing of TRT remain controversial.<OrderedList id="_339" Style="LAlpha">
     <ListItem>Multiple clinical trials and meta-analyses addressing the timing of TRT have been published, with the weight of evidence suggesting a small benefit to early TRT (i.e., TRT administered during the first or second cycle of chemotherapy administration).<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="15"/><Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/><Reference refidx="20"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem><ListItem>The amount of time from start to completion of TRT in LD SCLC may also affect overall survival (OS). In an analysis of four trials, the completion of therapy in less than 30 days was associated with an improved 5-year survival rate (relative risk,  0.62; 95% confidence interval [CI], 0.49–0.80; <Emphasis>P</Emphasis> = .0003).<Reference refidx="20"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem><ListItem>Both once-daily and twice-daily chest radiation schedules have been used in regimens with etoposide and cisplatin.<ItemizedList id="_485443" Style="bullet"><ListItem>One randomized study showed a modest survival advantage in favor of twice-daily radiation therapy given for 3 weeks, compared with once-daily radiation therapy to 45 Gy given for 5 weeks (26% vs. 16% at 5 years; <Emphasis>P</Emphasis> = .04).<Reference refidx="17"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] Esophagitis was increased with twice-daily treatment. </ListItem><ListItem>The phase III <ProtocolRef nct_id="NCT00433563">CONVERT</ProtocolRef> study (NCT00433563) randomly assigned patients to receive either 45 Gy radiation therapy in 30 twice-daily fractions of 1.5 Gy over 19 days or 66 Gy in 33 once-daily fractions of 2 Gy over 45 days, starting on day 22 after commencing cisplatin-etoposide chemotherapy (given as four to six cycles every 3 weeks in both groups).<Reference refidx="21"/> The primary end point was OS, defined as time from randomization until death from any cause, analyzed by modified intention-to-treat. A 12% higher OS at 2 years in the once-daily group versus the twice-daily group was considered clinically significant to show superiority of the once-daily regimen.<ItemizedList id="_485444" Style="dash"><ListItem>At a median follow-up of 45 months (interquartile range [IQR], 35–58), median OS was 30 months (95% CI, 24–34) in the twice-daily group versus 25 months (95% CI, 21–31) in the once-daily group (hazard ratio for death in the once-daily group, 1.18 [95% CI, 0.95–1.45]; <Emphasis>P</Emphasis> = .14).</ListItem><ListItem>The two-year OS rate was 56% (95% CI, 50%–62%) in the twice-daily group and 51% (45%–57%) in the once-daily group (absolute difference between the treatment groups, 5.3% [95% CI, -3.2% to 13.7%]).</ListItem><ListItem>Most toxicities were similar between the groups, except there was significantly more grade 4 neutropenia with twice-daily radiation therapy (129 [49%] vs. 101 [38%]; <Emphasis>P</Emphasis> = .05). In contrast to the earlier study, there was no difference between the groups in terms of rates of grade 3 to 4 esophagitis or pneumonitis.</ListItem></ItemizedList> </ListItem><ListItem>Twice-daily radiation therapy has not been broadly adopted. Once-daily fractions to doses higher than 60 Gy are feasible and commonly used; their clinical benefits are yet to be defined in phase III trials.<Reference refidx="21"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem></ItemizedList></ListItem></OrderedList></ListItem></OrderedList></SummarySection><SummarySection id="_485515"><Title>Adjuvant treatment after chemoradiation therapy</Title><Para id="_485516">Evidence (adjuvant treatment after chemoradiation therapy):</Para><OrderedList id="_485517" Style="Arabic"><ListItem>	<ProtocolRef nct_id="NCT03703297">ADRIATIC</ProtocolRef> (NCT03703297) was a phase III, randomized, double-blind, placebo-controlled, multicenter, global study, published in abstract form, that assessed durvalumab with or without tremelimumab as consolidation treatment for patients with LD SCLC. Patients had stage I to III disease (inoperable if stage I or II) that had not progressed after chemoradiation therapy. PCI was permitted before randomization. Patients were randomly assigned 1 to 42 days after concurrent chemoradiation therapy to receive durvalumab (1,500 mg) plus placebo, durvalumab (1,500 mg) plus tremelimumab (75 mg), or placebo plus placebo every 4 weeks for four cycles, followed by durvalumab or placebo every 4 weeks until investigator-determined progression or intolerable toxicity, or for a maximum of 24 months. The dual primary end points were OS and progression-free survival (PFS) per blinded independent central review for durvalumab versus placebo.  The trial randomly assigned 730 patients, including 264 to receive durvalumab and 266 to receive placebo. The abstract was published after the first planned interim analysis of durvalumab versus placebo.<Reference refidx="22"/><ItemizedList id="_485518" Style="bullet"><ListItem>The median duration of follow-up was 37.2 months for OS and 27.6 months for PFS.<Reference refidx="22"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem><ListItem>The median OS was 55.9 months in the durvalumab arm (95% CI, 37.3–not estimable) and 33.4 months in the placebo arm (95% CI, 25.5–39.9). The 24-month OS rate was 68.0% in the durvalumab arm and 58.5% in the placebo arm. The 36-month OS rate was 56.5% in the durvalumab arm and 47.6% in the placebo arm. </ListItem><ListItem>The median PFS was 16.6 months in the durvalumab arm (95% CI, 10.2–28.2) and 9.2 months (95% CI, 7.4–12.9) in the placebo arm. The 18-month PFS rate was 48.8% in the durvalumab arm and 36.1% in the placebo arm. The 24-month PFS rate was 46.2% in the durvalumab arm and 34.2% in the placebo arm.</ListItem><ListItem>	Grade 3 or 4 all-cause adverse events occurred in 24.3% of patients in the durvalumab arm and 24.2% of patients in the placebo arm. Adverse events led to treatment discontinuation in 16.3% of patients in the durvalumab arm and 10.6% of patients in the placebo arm, and to death in 2.7% of patients in the durvalumab arm and 1.9% of patients in the placebo arm. Any-grade pneumonitis/radiation pneumonitis was reported in 38.0% of patients who received durvalumab and 30.2% of patients who received the placebo.</ListItem></ItemizedList><Para id="_485519">This is the first new treatment option for patients with LD SCLC in over 35 years.</Para></ListItem></OrderedList></SummarySection><SummarySection id="_108"><Title>Combination chemotherapy alone</Title><Para id="_109">Patients with a contraindication to radiation therapy may receive chemotherapy alone. Patients presenting with superior vena cava syndrome are treated immediately with combination chemotherapy, radiation therapy, or both, depending on the severity of presentation.<Reference refidx="23"/><Reference refidx="24"/> For more information, see <SummaryRef href="CDR0000352186" url="/about-cancer/treatment/side-effects/cardiopulmonary-hp-pdq">Cardiopulmonary Syndromes</SummaryRef>.</Para></SummarySection><SummarySection id="_110"><Title>Surgery followed by chemotherapy or chemoradiation therapy</Title><Para id="_111">The role of surgery in the management of patients with SCLC is unproven.  Small case series and population studies have reported favorable outcomes for the  minority of LD patients with very limited disease, with small  tumors pathologically confined to the lung of origin or  the lung and ipsilateral hilar lymph nodes from surgical resection with adjuvant chemotherapy.<Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/><Reference refidx="28"/><Reference refidx="29"/>[<LOERef href="CDR0000810037" dictionary="NotSet" audience="Health professional">Level of evidence C2</LOERef>] Patients who have undergone surgery and then been diagnosed with SCLC generally receive adjuvant chemotherapy with or without radiation therapy. In patients who receive chemotherapy with radiation therapy, there is no improvement in survival with the addition of surgery.<Reference refidx="29"/>[<LOERef href="CDR0000810037" dictionary="NotSet" audience="Health professional">Level of evidence C2</LOERef>] Given the absence of data from randomized trials, the potential benefits and risks of surgery in the management of individual patients with SCLC must be considered.</Para><Para id="_322">Evidence (role of surgery):</Para><OrderedList id="_323" Style="Arabic">
     <ListItem>A randomized study evaluated the role of surgery in addition to chemoradiation therapy for 328 patients with LD SCLC. The study found no OS benefit with the addition of pulmonary resection.<Reference refidx="30"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem></OrderedList></SummarySection><SummarySection id="_114"><Title>PCI</Title><Para id="_115">Patients who have achieved a complete remission may receive PCI. Patients whose cancer can be controlled outside the brain have a 60% actuarial risk of developing central nervous system (CNS) metastases within 2 to 3 years after starting treatment.<Reference refidx="29"/><Reference refidx="31"/><Reference refidx="32"/> Most of these patients have disease that relapses only in the brain, and nearly all of those with CNS relapse die of their cranial metastases. The risk of developing CNS metastases can be reduced by more than 50% with the administration of PCI.<Reference refidx="31"/></Para><Para id="_324">Evidence (role of PCI):</Para><OrderedList id="_325" Style="Arabic">
     <ListItem>A meta-analysis of seven randomized trials evaluated the value of PCI for patients in complete remission. The addition of PCI improved the rates of brain recurrence, disease-free survival, and OS. The 3-year OS rate increased from 15% to 21% with PCI.<Reference refidx="31"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem><ListItem>The randomized RTOG-0212 study (<ProtocolRef nct_id="NCT00005062">NCT00005062</ProtocolRef>) included 720 patients with LD SCLC in complete remission after chemoradiation therapy. The trial demonstrated that standard-dose PCI (25 Gy in 10 fractions) was as effective as, and less toxic than, higher doses of brain radiation.<Reference refidx="33"/></ListItem><ListItem>Randomized trials such as  RTOG-0212 (<ProtocolRef nct_id="NCT00005062">NCT00005062</ProtocolRef>)   showed that doses higher than 25 Gy in 10 daily fractions do not improve long-term survival.<Reference refidx="33"/><Reference refidx="34"/><Reference refidx="35"/></ListItem></OrderedList></SummarySection><SummarySection id="_210"><Title>Neurological sequelae</Title><Para id="_235">Retrospective studies have shown that long-term survivors of SCLC (&gt;2 years from the start of treatment) have a high incidence of CNS impairment.<Reference refidx="29"/><Reference refidx="32"/><Reference refidx="36"/><Reference refidx="37"/><Reference refidx="38"/> Prospective studies have shown that patients treated with PCI do not have significantly worse neuropsychological function than patients not treated with PCI.<Reference refidx="38"/> Most patients with SCLC have neuropsychological abnormalities before the start of PCI and have no detectable neurological decline for as long as 2 years after the start of PCI.<Reference refidx="38"/> Patients treated for SCLC continue to have declining neuropsychological function after 2 years from the start of treatment.<Reference refidx="36"/><Reference refidx="37"/><Reference refidx="38"/> Additional neuropsychological testing of patients beyond 2 years from the start of treatment is needed before concluding that PCI does not contribute to the decline in intellectual function.</Para></SummarySection><SummarySection id="_211"><Title>Treatment options for older patients</Title><Para id="_105"> The optimal therapeutic approach in older patients remains unclear. A population analysis showed that increasing age was associated with decreased performance status and increased comorbidity.<Reference refidx="39"/> Older patients were less likely to be treated with combined chemoradiation therapy, more intensive chemotherapy, and PCI. Older patients were also less likely to respond to therapy and had poorer survival outcomes. Whether these findings were a result of age and its associated comorbidities or suboptimal treatment delivery remains uncertain.</Para><Para id="_212">No specific phase III trial in older patients with LD SCLC has been reported. However, three secondary analyses of two cooperative group trials evaluating outcomes in patients aged 70 years or older have been published.<Reference refidx="40"/><Reference refidx="41"/><Reference refidx="42"/> The survival outcomes for the older patients were identical to those of their younger counterparts in both trials. The older patients experienced more toxic effects, particularly hematological, compared with younger patients. There was a significant increase in treatment-related mortality in the EST-3588 trial that compared etoposide and cisplatin with either once-daily or twice-daily radiation therapy (1% for patients aged &lt;70 years vs. 10% for patients aged ≥70 years; <Emphasis>P</Emphasis> = .01).<Reference refidx="41"/> Because the older patients enrolled in these phase III trials may not be representative of LD SCLC patients in the general population, caution must be exercised in extrapolating these results to the general population of older patients.</Para></SummarySection></SummarySection><SummarySection id="_TrialSearch_83_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_83_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="1331787" MedlineID="93063085">Pignon JP, Arriagada R, Ihde DC, et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327 (23): 1618-24, 1992.</Citation><Citation idx="2" PMID="1316951" MedlineID="92268942">Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10 (6): 890-5, 1992.</Citation><Citation idx="3" PMID="8381164" MedlineID="93147868">Murray N, Coy P, Pater JL, et al.: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11 (2): 336-44, 1993.</Citation><Citation idx="4" PMID="2175739" MedlineID="91086160">Turrisi AT, Glover DJ: Thoracic radiotherapy variables: influence on local control in small cell lung cancer limited disease. Int J Radiat Oncol Biol Phys 19 (6): 1473-9, 1990.</Citation><Citation idx="5" PMID="2159055" MedlineID="90237845">McCracken JD, Janaki LM, Crowley JJ, et al.: Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. J Clin Oncol 8 (5): 892-8, 1990.</Citation><Citation idx="6" PMID="12118018">Takada M, Fukuoka M, Kawahara M, et al.: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20 (14): 3054-60, 2002.</Citation><Citation idx="7" PMID="8622028" MedlineID="96186206">Johnson BE, Bridges JD, Sobczeck M, et al.: Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 14 (3): 806-13, 1996.</Citation><Citation idx="8" PMID="16921033">Spiro SG, James LE, Rudd RM, et al.: Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol 24 (24): 3823-30, 2006.</Citation><Citation idx="9" PMID="16344277">De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, et al.: Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 17 (4): 543-52, 2006.</Citation><Citation idx="10" PMID="8391065" MedlineID="93301655">Giaccone G, Dalesio O, McVie GJ, et al.: Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 11 (7): 1230-40, 1993.</Citation><Citation idx="11" PMID="2153194" MedlineID="90111794">Goodman GE, Crowley JJ, Blasko JC, et al.: Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. J Clin Oncol 8 (1): 39-47, 1990.</Citation><Citation idx="12" PMID="1648142" MedlineID="91287135">Fukuoka M, Furuse K, Saijo N, et al.: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83 (12): 855-61, 1991.</Citation><Citation idx="13" PMID="8260367" MedlineID="94083273">Bleehen NM, Girling DJ, Machin D, et al.: A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party. Br J Cancer 68 (6): 1150-6, 1993.</Citation><Citation idx="14" PMID="8708726" MedlineID="96326435">Sculier JP, Paesmans M, Bureau G, et al.: Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 14 (8): 2337-44, 1996.</Citation><Citation idx="15" PMID="15570087">Fried DB, Morris DE, Poole C, et al.: Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22 (23): 4837-45, 2004.</Citation><Citation idx="16" PMID="24309370">Kubota K, Hida T, Ishikura S, et al.: Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol 15 (1): 106-13, 2014.</Citation><Citation idx="17" PMID="9920950" MedlineID="99110542">Turrisi AT, Kim K, Blum R, et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 (4): 265-71, 1999.</Citation><Citation idx="18" PMID="15561810">Huncharek M, McGarry R: A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 9 (6): 665-72, 2004.</Citation><Citation idx="19" PMID="15674960">Pijls-Johannesma MC, De Ruysscher D, Lambin P, et al.: Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev  (1): CD004700, 2005.</Citation><Citation idx="20" PMID="16505424">De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al.: Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24 (7): 1057-63, 2006.</Citation><Citation idx="21" PMID="28642008">Faivre-Finn C, Snee M, Ashcroft L, et al.: Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 18 (8): 1116-1125, 2017.</Citation><Citation idx="22">Spigel DR, Cheng Y, Cho BC, et al.: ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). [Abstract] J Clin Oncol  42 (Suppl 17): A-LBA5, 2024.</Citation><Citation idx="23" PMID="8381263" MedlineID="93151695">Urban T, Lebeau B, Chastang C, et al.: Superior vena cava syndrome in small-cell lung cancer. Arch Intern Med 153 (3): 384-7, 1993.</Citation><Citation idx="24" PMID="7642434" MedlineID="95370067">Würschmidt F, Bünemann H, Heilmann HP: Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. Int J Radiat Oncol Biol Phys 33 (1): 77-82, 1995.</Citation><Citation idx="25" PMID="2992111" MedlineID="85273257">Osterlind K, Hansen M, Hansen HH, et al.: Treatment policy of surgery in small cell carcinoma of the lung: retrospective analysis of a series of 874 consecutive patients. Thorax 40 (4): 272-7, 1985.</Citation><Citation idx="26" PMID="2536868" MedlineID="89126454">Shepherd FA, Ginsberg RJ, Patterson GA, et al.: A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancer. A University of Toronto Lung Oncology Group study. J Thorac Cardiovasc Surg 97 (2): 177-86, 1989.</Citation><Citation idx="27" PMID="2556806" MedlineID="90085087">Prasad US, Naylor AR, Walker WS, et al.: Long term survival after pulmonary resection for small cell carcinoma of the lung. Thorax 44 (10): 784-7, 1989.</Citation><Citation idx="28" PMID="8153935" MedlineID="94204986">Smit EF, Groen HJ, Timens W, et al.: Surgical resection for small cell carcinoma of the lung: a retrospective study. Thorax 49 (1): 20-2, 1994.</Citation><Citation idx="29" PMID="16706259">Chandra V, Allen MS, Nichols FC, et al.: The role of pulmonary resection in small cell lung cancer. Mayo Clin Proc 81 (5): 619-24, 2006.</Citation><Citation idx="30" PMID="7988254">Lad T, Piantadosi S, Thomas P, et al.: A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 106 (6 Suppl): 320S-323S, 1994.</Citation><Citation idx="31" PMID="227582" MedlineID="80044617">Nugent JL, Bunn PA, Matthews MJ, et al.: CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer 44 (5): 1885-93, 1979.</Citation><Citation idx="32" PMID="10441603" MedlineID="99353503">Aupérin A, Arriagada R, Pignon JP, et al.: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341 (7): 476-84, 1999.</Citation><Citation idx="33" PMID="19386548">Le Péchoux C, Dunant A, Senan S, et al.: Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 10 (5): 467-74, 2009.</Citation><Citation idx="34" PMID="21139020">Le Péchoux C, Laplanche A, Faivre-Finn C, et al.: Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol 22 (5): 1154-63, 2011.</Citation><Citation idx="35" PMID="20800380">Wolfson AH, Bae K, Komaki R, et al.: Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 81 (1): 77-84, 2011.</Citation><Citation idx="36" PMID="2153196" MedlineID="90111796">Johnson BE, Patronas N, Hayes W, et al.: Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung cancer: further follow-up of 6- to 13-year survivors. J Clin Oncol 8 (1): 48-56, 1990.</Citation><Citation idx="37" PMID="2838443" MedlineID="88256772">Laukkanen E, Klonoff H, Allan B, et al.: The role of prophylactic brain irradiation in limited stage small cell lung cancer: clinical, neuropsychologic, and CT sequelae. Int J Radiat Oncol Biol Phys 14 (6): 1109-17, 1988.</Citation><Citation idx="38" PMID="7654431" MedlineID="95383028">Cull A, Gregor A, Hopwood P, et al.: Neurological and cognitive impairment in long-term survivors of small cell lung cancer. Eur J Cancer 30A (8): 1067-74, 1994.</Citation><Citation idx="39" PMID="12654444">Ludbrook JJ, Truong PT, MacNeil MV, et al.: Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. Int J Radiat Oncol Biol Phys 55 (5): 1321-30, 2003.</Citation><Citation idx="40" PMID="12874270">Schild SE, Stella PJ, Geyer SM, et al.: The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21 (17): 3201-6, 2003.</Citation><Citation idx="41" PMID="11064352" MedlineID="20519297">Yuen AR, Zou G, Turrisi AT, et al.: Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 89 (9): 1953-60, 2000.</Citation><Citation idx="42" PMID="8622030">Siu LL, Shepherd FA, Murray N, et al.: Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol 14 (3): 821-8, 1996.</Citation></ReferenceSection></SummarySection><SummarySection id="_124"><SectMetaData><SpecificDiagnosis ref="CDR0000037829">extensive stage small cell lung cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Extensive-Stage SCLC</Title><SummarySection id="_153"><Title>Treatment Options for Patients With Extensive-Stage SCLC</Title><Para id="_125">Treatment options for patients with <SummaryRef href="CDR0000062945#_270" url="/types/lung/hp/small-cell-lung-treatment-pdq">extensive-stage disease (ED) small cell lung cancer (SCLC)</SummaryRef> include:</Para><OrderedList id="_126" Style="Arabic">
     <ListItem><SummaryRef href="CDR0000062945#_485448" url="/types/lung/hp/small-cell-lung-treatment-pdq">Immune checkpoint modulation and combination chemotherapy</SummaryRef>.<ItemizedList id="_485496" Style="bullet"><ListItem><SummaryRef href="CDR0000062945#_485450" url="/types/lung/hp/small-cell-lung-treatment-pdq">Atezolizumab</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062945#_485450" url="/types/lung/hp/small-cell-lung-treatment-pdq">Durvalumab</SummaryRef>.</ListItem></ItemizedList></ListItem><ListItem><SummaryRef href="CDR0000062945#_127" url="/types/lung/hp/small-cell-lung-treatment-pdq">Combination chemotherapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062945#_155" url="/types/lung/hp/small-cell-lung-treatment-pdq">Radiation therapy</SummaryRef>.<ItemizedList id="_485497" Style="bullet"><ListItem><SummaryRef href="CDR0000062945#_309" url="/types/lung/hp/small-cell-lung-treatment-pdq">Thoracic radiation therapy for patients who respond to chemotherapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062945#_157" url="/types/lung/hp/small-cell-lung-treatment-pdq">Prophylactic cranial irradiation (PCI)</SummaryRef>.</ListItem></ItemizedList></ListItem><ListItem>Clinical trials evaluating new drug regimens or alternative drug doses and schedules.</ListItem></OrderedList><SummarySection id="_485448"><Title>Immune checkpoint modulation and combination chemotherapy</Title><Para id="_485449">Studies have evaluated the role of immune checkpoint inhibitors (programmed cell death-1 [PD-1] or programmed death-ligand 1  [PD-L1] inhibitors) in frontline treatment of patients with ED SCLC. Two PD-L1 inhibitors, atezolizumab and durvalumab, prolonged overall survival (OS) when combined with platinum and etoposide, compared with the same combination chemotherapy regimen alone. For more information, see the <SummaryRef href="CDR0000062945#_127" url="/types/lung/hp/small-cell-lung-treatment-pdq">Combination chemotherapy</SummaryRef> section. Treatment with a PD-1 inhibitor, pembrolizumab, in combination with chemotherapy, did not meet statistical significance for the prespecified end point of OS in the <ProtocolRef nct_id="NCT03066778">KEYNOTE-604</ProtocolRef> (NCT03066778) phase III trial.<Reference refidx="1"/>[<LOERef href="CDR0000810025" dictionary="NotSet" audience="Health professional">Level of evidence B1</LOERef>]</Para><Para id="_485453">Evidence (immune checkpoint modulation and combination chemotherapy):</Para><OrderedList id="_485450" Style="Arabic"><ListItem>	<Strong>Atezolizumab</Strong>. <ProtocolRef nct_id="NCT02763579">IMpower133</ProtocolRef> (NCT02763579), a double-blind, placebo-controlled, randomized, phase III trial, compared four cycles of carboplatin and etoposide with either atezolizumab (n = 201) or placebo (n = 202), followed by maintenance with either atezolizumab or placebo (as per the original randomization) until unacceptable toxic effects, disease progression, or no additional benefit.<Reference refidx="2"/><ItemizedList id="_485451" Style="bullet"><ListItem>	At the planned interim analysis for OS, with a median follow-up of 22.9 months, the median OS was 12.3 months in the atezolizumab group and 10.3 months in the placebo group (hazard ratio [HR] for death, 0.76; 95% confidence interval [CI], 0.60−0.95; descriptive <Emphasis>P</Emphasis> = .0154).<Reference refidx="2"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] </ListItem><ListItem>	The median progression-free survival (PFS) was 5.2 months for the atezolizumab group and 4.3 months for the placebo group (HR for disease progression or death, 0.77; 95% CI, 0.63−0.95; <Emphasis>P</Emphasis> = .02). </ListItem><ListItem>	The toxicity event rate was similar for both arms, consistent with known adverse events of the individual agents. Grade 3 or 4 adverse events occurred in 56.6% of patients in the atezolizumab group and 56.1% of patients in the placebo group.</ListItem></ItemizedList></ListItem><ListItem><Strong>Durvalumab</Strong>. <ProtocolRef nct_id="NCT03043872">CASPIAN</ProtocolRef> (NCT03043872) was a randomized, open-label, phase III trial that assigned patients to durvalumab plus platinum-etoposide (n = 268), durvalumab plus tremelimumab (a cytotoxic T lymphocyte antigen-4 [CTLA-4] inhibitor) plus platinum-etoposide (n = 268), or platinum-etoposide alone (n = 269). In the immunotherapy arms, patients received four cycles of platinum-etoposide plus durvalumab with or without tremelimumab, followed by durvalumab maintenance until intolerance or disease progression or until other discontinuation criteria were met. In the chemotherapy-alone arm, up to six cycles of chemotherapy could be given, as well as PCI, at the investigator’s discretion. At the time of planned interim OS analysis, the durvalumab plus platinum-etoposide group met the predefined threshold for statistical significance.<Reference refidx="3"/>  <ItemizedList id="_485452" Style="bullet"><ListItem>	The median OS was  12.9 months in the durvalumab plus platinum-etoposide group versus 10.5 months in the platinum-etoposide group (HR for OS, 0.75; 95% CI, 0.62−0.91; nominal <Emphasis>P</Emphasis> = .0032).<Reference refidx="3"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] </ListItem><ListItem>	The toxicity event rate was similar in both arms, consistent with known adverse events of the individual agents. Grade 3 or 4 events occurred in 62% of patients in both study arms. </ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_127"><Title>Combination chemotherapy</Title><Para id="_128">Chemotherapy for patients with ED SCLC is commonly given as a two-drug combination of platinum and etoposide in doses associated with at least moderate toxic effects (as in limited-stage [LD] SCLC).<Reference refidx="4"/> Cisplatin is associated with significant toxic effects and requires fluid hydration, which can be problematic in patients with cardiovascular disease. Carboplatin is active in SCLC, is dosed according to renal function, and is associated with less nonhematological toxic effects.</Para><Para id="_213">Other regimens appear to produce similar survival outcomes but have been studied less extensively or are in less common use.</Para><Table id="_136"><Title>Table 2.  Combination Chemotherapy for Extensive-Stage SCLC</Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="34.36%"/><ColSpec ColName="col2" ColNum="2" ColWidth="65.63%"/><TBody><Row><entry MoreRows="1">Standard treatment</entry><entry>Etoposide + cisplatin</entry></Row><Row><entry>Etoposide + carboplatin</entry></Row><Row><entry MoreRows="5">Other regimens</entry><entry>Cisplatin + irinotecan</entry></Row><Row><entry>Ifosfamide + cisplatin + etoposide</entry></Row><Row><entry>Cyclophosphamide + doxorubicin + etoposide</entry></Row><Row><entry>Cyclophosphamide + doxorubicin + etoposide + vincristine</entry></Row><Row><entry>Cyclophosphamide + etoposide + vincristine</entry></Row><Row><entry>Cyclophosphamide + doxorubicin + vincristine</entry></Row></TBody></TGroup></Table><Para id="_214">Doses and schedules used in current programs yield overall response rates of 50% to 80% and complete response rates of 0% to 30% in patients with ED SCLC.<Reference refidx="5"/><Reference refidx="6"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</Para><Para id="_215">Intracranial metastases from small cell carcinoma may respond to chemotherapy as readily as metastases in other organs.<Reference refidx="7"/><Reference refidx="8"/></Para><Para id="_327">Evidence (standard regimens):</Para><OrderedList id="_328" Style="Arabic">
     <ListItem>Two meta-analyses evaluated the role of  platinum combinations versus nonplatinum combinations.<ItemizedList id="_329" Style="bullet">
     <ListItem>A Cochrane analysis did not identify a difference in 6-, 12-, or 24-month survival.<Reference refidx="9"/></ListItem><ListItem>A meta-analysis of 19 trials published between 1981 and 1999 showed a significant survival advantage for patients receiving platinum-based chemotherapy compared with those receiving a nonplatinum agent.<Reference refidx="6"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem></ItemizedList></ListItem><ListItem>The Hellenic Oncology Group conducted a phase III trial comparing cisplatin and etoposide with carboplatin plus etoposide.<Reference refidx="10"/> The median survival was 11.8 months in the cisplatin arm and 12.5 months in the carboplatin arm.<Reference refidx="10"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] Although this difference was not statistically significant, the trial was underpowered to prove equivalence of the two treatment regimens in patients with either LD or ED.</ListItem></OrderedList><Para id="_330">Evidence (other combination chemotherapy regimens):</Para><OrderedList id="_331" Style="Arabic">
     <ListItem><Strong>Irinotecan.</Strong> Five trials and two meta-analyses have evaluated the combination of etoposide and cisplatin versus irinotecan and cisplatin.  Only one of the trials showed the superiority of the irinotecan-and-cisplatin combination.<Reference refidx="11"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]  Subsequent trials and the meta-analyses support that the regimens provide equivalent clinical benefit with differing toxicity profiles.<Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] Irinotecan-and-cisplatin regimens led to less grade 3 to 4 anemia, neutropenia, and thrombocytopenia but more grade 3 to 4 vomiting and diarrhea than  etoposide-and-cisplatin regimens. Treatment-related deaths were comparable between the two groups.</ListItem><ListItem><Strong>Topotecan.</Strong> In a randomized trial of 784 patients, the combination of oral topotecan given with cisplatin for 5 days was not superior to etoposide and cisplatin.<Reference refidx="18"/> The 1-year survival rate was 31% (95% CI, 27%–36%) and was deemed to be noninferior, as the difference of -0.03 met the predefined criteria of no more than 10% absolute difference in 1-year survival.<Reference refidx="18"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem><ListItem><Strong>Paclitaxel.</Strong> No consistent survival benefit has resulted from the addition of paclitaxel to etoposide and cisplatin.<Reference refidx="19"/><Reference refidx="20"/></ListItem></OrderedList><Para id="_353">Evidence (duration of treatment):</Para><OrderedList id="_354" Style="Arabic">
     <ListItem>The optimal duration of chemotherapy is not clearly defined, but no obvious improvement in survival occurs when the duration of drug administration exceeds 6 months.<Reference refidx="10"/><Reference refidx="21"/><Reference refidx="22"/></ListItem><ListItem>Reported data from randomized trials show no clear evidence that maintenance chemotherapy improves survival duration.<Reference refidx="23"/><Reference refidx="24"/><Reference refidx="25"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] However, a meta-analysis of 14 published randomized trials assessing the benefit of duration/maintenance therapy reported an odds ratio of 0.67 for both 1- and 2-year OS (95% CI, 0.56–0.79; <Emphasis>P</Emphasis> &lt; .001 for 1-year OS and 0.53–0.86; <Emphasis>P</Emphasis> &lt; .001 for 2-year OS). This corresponded to an increase of 9% in 1-year OS and 4% in 2-year OS.<Reference refidx="26"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem></OrderedList><Para id="_356">Evidence (dose intensification):</Para><OrderedList id="_357" Style="Arabic">
     <ListItem>The role of dose intensification in patients with SCLC remains unclear.<Reference refidx="27"/><Reference refidx="28"/><Reference refidx="29"/><Reference refidx="30"/><Reference refidx="31"/> Early studies showed that under-treatment compromised outcome and suggested that early dose intensification may improve survival.<Reference refidx="27"/><Reference refidx="28"/> A number of clinical trials have examined the use of colony-stimulating factors to support dose-intensified chemotherapy in SCLC.<Reference refidx="29"/><Reference refidx="30"/><Reference refidx="31"/><Reference refidx="32"/><Reference refidx="33"/><Reference refidx="34"/><Reference refidx="35"/><Reference refidx="36"/><Reference refidx="37"/> These studies have yielded conflicting results.<ItemizedList id="_358" Style="bullet">
     <ListItem>Four studies have shown that a modest increase in dose intensity (25%–34%) was associated with a significant improvement in survival, with no compromise in quality of life (QOL).<Reference refidx="29"/><Reference refidx="30"/><Reference refidx="31"/><Reference refidx="32"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem><ListItem>Two of three studies that examined combinations of the variables of interval, dose per cycle, and number of cycles showed no advantage.<Reference refidx="32"/><Reference refidx="33"/><Reference refidx="34"/><Reference refidx="35"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem><ListItem>The European Organisation for Research and Treatment of Cancer trial (<ExternalRef xref="http://www.eortc.org/research_field/clinical-detail/08923/">EORTC-08923</ExternalRef>) reported a randomized comparison  of standard-dose cyclophosphamide, doxorubicin, and etoposide given every 3 weeks for five cycles versus intensified treatment given at 125% of the dose every 2 weeks for four cycles with granulocyte colony-stimulating factor (G-CSF) support.<Reference refidx="35"/> The median dose intensity delivered was 70% higher in the experimental arm; the median cumulative dose was similar in both arms. There was no difference between treatment groups in median or 2-year survival.</ListItem><ListItem>A randomized phase III trial compared ifosfamide, cisplatin, and etoposide (ICE), which was given every 4 weeks, with twice weekly ICE with G-CSF and autologous blood support.<Reference refidx="36"/> Despite achieving a relative dose intensity of 1.84 in the dose-accelerated arm, there was no difference in response rate (88% vs. 80%, respectively), median survival (14.4 vs. 13.9 months, respectively), or 2-year survival (19% vs. 22%, respectively) for dose-dense treatment compared with standard treatment.<Reference refidx="36"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] Patients who received dose-dense treatment spent less time on treatment and had fewer episodes of infection.</ListItem><ListItem>A randomized phase II study of identical design reported a significantly better median survival for the dose-dense arm (29.8 vs. 17.4 months, respectively; <Emphasis>P</Emphasis> = .02) and 2-year survival (62% vs. 36%, respectively; <Emphasis>P</Emphasis> = .05).<Reference refidx="37"/> However, given the small study size (only 70 patients), these results should be viewed with caution.</ListItem></ItemizedList></ListItem></OrderedList><SummarySection id="_224"><Title>Factors influencing treatment with chemotherapy</Title><OrderedList id="_485454" Style="Arabic"><ListItem>Performance status.<Para id="_485455">More patients with ED SCLC have greatly impaired performance status at the time of diagnosis than patients with LD. Such patients have a poor prognosis and tolerate aggressive chemotherapy or combined-modality therapy poorly. Single-agent intravenous, oral, and low-dose biweekly regimens have been developed for these patients.<Reference refidx="33"/><Reference refidx="38"/><Reference refidx="39"/><Reference refidx="40"/><Reference refidx="41"/><Reference refidx="42"/><Reference refidx="43"/><Reference refidx="44"/></Para><Para id="_485456">Prospective randomized studies have shown that patients with a poor prognosis who are treated with conventional regimens live longer than those treated with single-agent, low-dose regimens or abbreviated courses of therapy. A study comparing chemotherapy every 3 weeks with treatment given as required for symptom control showed an improvement in QOL in patients receiving regular treatment.<Reference refidx="41"/>[<LOERef href="CDR0000810025" dictionary="NotSet" audience="Health professional">Level of evidence B1</LOERef>]</Para><Para id="_485457">Other studies have tested intensive one-drug or two-drug regimens. A study conducted by the Medical Research Council demonstrated similar efficacy for an etoposide-plus-vincristine regimen and a four-drug regimen.<Reference refidx="42"/> The latter regimen was associated with a greater risk of toxic effects and early death but was superior with respect to palliation of symptoms and psychological distress.<Reference refidx="42"/>[<LOERef href="CDR0000810021" dictionary="NotSet" audience="Health professional">Level of evidence A3</LOERef>] Studies comparing a convenient oral treatment with single-agent oral etoposide versus combination therapy showed that the overall response rate and OS were significantly worse in the oral etoposide arm.<Reference refidx="38"/><Reference refidx="43"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</Para></ListItem><ListItem>Age.<Para id="_485458">Subgroup analyses of phase II and III trials of patients with SCLC by age showed that myelosuppression and doxorubicin-induced cardiac toxic effects were more severe in older patients than in younger patients, and that the incidence of treatment-related death tended to be higher in older patients.<Reference refidx="44"/> About 80% of older patients, however, received optimal treatment, and their survival was comparable with that of younger patients. The standard chemotherapy regimens for the general population could be applied to older patients in good general condition (i.e., performance status of 0–1, normal organ function, and no comorbidity). There is no evidence of a difference in response rate, disease-free survival (DFS), or OS in older patients compared with younger patients.</Para></ListItem></OrderedList></SummarySection></SummarySection><SummarySection id="_155"><Title>Radiation therapy</Title><Para id="_156">Radiation therapy to sites of metastatic disease unlikely to be immediately palliated by chemotherapy, especially brain, epidural, and bone metastases, is a standard treatment option for patients with ED SCLC. Brain metastases are treated with whole-brain radiation therapy.</Para><Para id="_161">Chest radiation therapy is sometimes given for superior vena cava syndrome, but chemotherapy alone, with radiation reserved for nonresponding patients, is appropriate initial treatment. For more information, see <SummaryRef href="CDR0000352186" url="/about-cancer/treatment/side-effects/cardiopulmonary-hp-pdq">Cardiopulmonary Syndromes</SummaryRef>.</Para><SummarySection id="_309"><Title>Thoracic radiation therapy for patients who respond to chemotherapy</Title><Para id="_310">Patients with ED SCLC treated with chemotherapy who have achieved a response may receive thoracic radiation therapy.</Para><Para id="_311">Evidence (thoracic radiation therapy):</Para><OrderedList id="_312" Style="Arabic"><ListItem>A randomized trial of 498 patients who responded after receiving four to six cycles of chemotherapy compared thoracic radiation therapy with 30 Gy in 10 fractions versus no radiation therapy.  All patients received PCI.<Reference refidx="45"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]<ItemizedList id="_313" Style="bullet"><ListItem>OS was the primary study end point and not statistically different between the two groups at 1 year (33% for the thoracic radiation therapy group vs. 28% for the control group, <Emphasis>P</Emphasis> = .066).</ListItem><ListItem>However, in a secondary analysis, the 2-year OS rate was 13% in the thoracic radiation group (95% CI, 9%–19%) versus 3% in the control group (95% CI, 2%–8%; <Emphasis>P</Emphasis> = .004). The OS  during the entire course of follow-up was not reported.</ListItem><ListItem>	Thoracic radiation therapy resulted in a 6-month PFS rate of 24% in the thoracic radiation group (95% CI, 19%–30%) versus 7% in the control group (95% CI, 4%–11%; <Emphasis>P</Emphasis> = .001).</ListItem><ListItem>	Intrathoracic recurrences, both isolated (19.8% vs. 46.0%) and in combination with recurrences at other sites (43.7% vs. 79.8%), were reduced by approximately 50%. </ListItem><ListItem>	Thoracic radiation therapy was well tolerated.</ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_157"><Title>PCI</Title><Para id="_158">Patients with ED treated with chemotherapy who have achieved a response can be considered for administration of PCI.</Para><Para id="_359">Evidence (PCI):</Para><OrderedList id="_360" Style="Arabic">
     <ListItem>A randomized trial of 286 patients who responded after four to six cycles of chemotherapy compared PCI with no further therapy.<Reference refidx="46"/>[<LOERef href="CDR0000810025" dictionary="NotSet" audience="Health professional">Level of evidence B1</LOERef><ItemizedList id="_361" Style="bullet">
     <ListItem>The cumulative risk of brain metastases within 1 year was 14.6% in the radiation group (95% CI, 8.3%–20.9%) and 40.4% in the control group (95% CI, 32.1%– 48.6%).</ListItem><ListItem> Radiation was associated with an increase in median DFS from 12.0 weeks to 14.7 weeks and in median OS from 5.4 months to 6.7 months after randomization.</ListItem><ListItem>The 1-year survival rate was 27.1% (95% CI, 19.4%–35.5%) in the radiation group and 13.3% (95% CI, 8.1%–19.9%) in the control group.<Reference refidx="46"/></ListItem><ListItem>Radiation had side effects but did not have a clinically significant effect on global health status.<Reference refidx="46"/></ListItem><ListItem>Only 29% of the randomly assigned patients had brain imaging at diagnosis.<Reference refidx="47"/></ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_162"><Title>Combination chemotherapy and radiation therapy</Title><Para id="_163">Combination chemotherapy plus chest radiation therapy does not appear to improve survival compared with chemotherapy alone in patients with ED SCLC.</Para></SummarySection></SummarySection></SummarySection><SummarySection id="_TrialSearch_124_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_124_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="32468956">Rudin CM, Awad MM, Navarro A, et al.: Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol 38 (21): 2369-2379, 2020.</Citation><Citation idx="2" PMID="33439693">Liu SV, Reck M, Mansfield AS, et al.: Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol 39 (6): 619-630, 2021.</Citation><Citation idx="3" PMID="33285097">Goldman JW, Dvorkin M, Chen Y, et al.: Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 22 (1): 51-65, 2021.</Citation><Citation idx="4" PMID="17579629">Okamoto H, Watanabe K, Kunikane H, et al.: Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 97 (2): 162-9, 2007.</Citation><Citation idx="5" PMID="1310103" MedlineID="92121940">Roth BJ, Johnson DH, Einhorn LH, et al.: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10 (2): 282-91, 1992.</Citation><Citation idx="6" PMID="10883661">Pujol JL, Carestia L, Daurès JP: Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83 (1): 8-15, 2000.</Citation><Citation idx="7" PMID="2153393" MedlineID="90122567">Twelves CJ, Souhami RL, Harper PG, et al.: The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br J Cancer 61 (1): 147-50, 1990.</Citation><Citation idx="8" PMID="227582" MedlineID="80044617">Nugent JL, Bunn PA, Matthews MJ, et al.: CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer 44 (5): 1885-93, 1979.</Citation><Citation idx="9" PMID="18843733">Amarasena IU, Walters JA, Wood-Baker R, et al.: Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev  (4): CD006849, 2008.</Citation><Citation idx="10" PMID="2540789" MedlineID="89228887">Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 59 (4): 584-90, 1989.</Citation><Citation idx="11" PMID="11784874" MedlineID="21644487">Noda K, Nishiwaki Y, Kawahara M, et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2): 85-91, 2002.</Citation><Citation idx="12" PMID="16648503">Hanna N, Bunn PA, Langer C, et al.: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 (13): 2038-43, 2006.</Citation><Citation idx="13" PMID="19349543">Lara PN, Natale R, Crowley J, et al.: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27 (15): 2530-5, 2009.</Citation><Citation idx="14" PMID="21266516">Schmittel A, Sebastian M, Fischer von Weikersthal L, et al.: A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 22 (8): 1798-804, 2011.</Citation><Citation idx="15" PMID="20231298">Zatloukal P, Cardenal F, Szczesna A, et al.: A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 21 (9): 1810-6, 2010.</Citation><Citation idx="16" PMID="20521354">Jiang J, Liang X, Zhou X, et al.: A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 5 (6): 867-73, 2010.</Citation><Citation idx="17" PMID="21252725">Guo S, Liang Y, Zhou Q: Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy. J Thorac Oncol 6 (2): 406-8; author reply 408, 2011.</Citation><Citation idx="18" PMID="16648504">Eckardt JR, von Pawel J, Papai Z, et al.: Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 24 (13): 2044-51, 2006.</Citation><Citation idx="19" PMID="11398877">Mavroudis D, Papadakis E, Veslemes M, et al.: A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 12 (4): 463-70, 2001.</Citation><Citation idx="20" PMID="15923572">Niell HB, Herndon JE, Miller AA, et al.: Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23 (16): 3752-9, 2005.</Citation><Citation idx="21" PMID="2540788" MedlineID="89228886">Spiro SG, Souhami RL, Geddes DM, et al.: Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 59 (4): 578-83, 1989.</Citation><Citation idx="22" PMID="8260367" MedlineID="94083273">Bleehen NM, Girling DJ, Machin D, et al.: A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party. Br J Cancer 68 (6): 1150-6, 1993.</Citation><Citation idx="23" PMID="8391065" MedlineID="93301655">Giaccone G, Dalesio O, McVie GJ, et al.: Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 11 (7): 1230-40, 1993.</Citation><Citation idx="24" PMID="8708726" MedlineID="96326435">Sculier JP, Paesmans M, Bureau G, et al.: Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 14 (8): 2337-44, 1996.</Citation><Citation idx="25" PMID="11304763" MedlineID="21201271">Schiller JH, Adak S, Cella D, et al.: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19 (8): 2114-22, 2001.</Citation><Citation idx="26" PMID="16284984">Bozcuk H, Artac M, Ozdogan M, et al.: Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials. Cancer 104 (12): 2650-7, 2005.</Citation><Citation idx="27" PMID="194691">Cohen MH, Creaven PJ, Fossieck BE, et al.: Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 61 (3): 349-54, 1977 May-Jun.</Citation><Citation idx="28" PMID="8247036" MedlineID="94067212">Arriagada R, Le Chevalier T, Pignon JP, et al.: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 329 (25): 1848-52, 1993.</Citation><Citation idx="29" PMID="9010043">Fukuoka M, Masuda N, Negoro S, et al.: CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 75 (2): 306-9, 1997.</Citation><Citation idx="30" PMID="7533825">Woll PJ, Hodgetts J, Lomax L, et al.: Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 13 (3): 652-9, 1995.</Citation><Citation idx="31" PMID="9469353">Steward WP, von Pawel J, Gatzemeier U, et al.: Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 16 (2): 642-50, 1998.</Citation><Citation idx="32" PMID="10637255" MedlineID="20105386">Thatcher N, Girling DJ, Hopwood P, et al.: Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 18 (2): 395-404, 2000.</Citation><Citation idx="33" PMID="8664131" MedlineID="96262142">James LE, Gower NH, Rudd RM, et al.: A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial. Br J Cancer 73 (12): 1563-8, 1996.</Citation><Citation idx="34" PMID="9164221">Pujol JL, Douillard JY, Rivière A, et al.: Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 15 (5): 2082-9, 1997.</Citation><Citation idx="35" PMID="12351591" MedlineID="22239090">Ardizzoni A, Tjan-Heijnen VC, Postmus PE, et al.: Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 20 (19): 3947-55, 2002.</Citation><Citation idx="36" PMID="15870437">Lorigan P, Woll PJ, O'Brien ME, et al.: Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 97 (9): 666-74, 2005.</Citation><Citation idx="37" PMID="17410010">Buchholz E, Manegold C, Pilz L, et al.: Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis. J Thorac Oncol 2 (1): 51-8, 2007.</Citation><Citation idx="38" PMID="8774567" MedlineID="96370671">Girling DJ: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 348 (9027): 563-6, 1996.</Citation><Citation idx="39" PMID="9779708">Murray N, Grafton C, Shah A, et al.: Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol 16 (10): 3323-8, 1998.</Citation><Citation idx="40" PMID="9586913">Westeel V, Murray N, Gelmon K, et al.: New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen. J Clin Oncol 16 (5): 1940-7, 1998.</Citation><Citation idx="41" PMID="1654983">Earl HM, Rudd RM, Spiro SG, et al.: A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 64 (3): 566-72, 1991.</Citation><Citation idx="42" PMID="8562352">Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party. Br J Cancer 73 (3): 406-13, 1996.</Citation><Citation idx="43" PMID="9106647" MedlineID="97260527">Souhami RL, Spiro SG, Rudd RM, et al.: Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89 (8): 577-80, 1997.</Citation><Citation idx="44" PMID="15145510">Sekine I, Yamamoto N, Kunitoh H, et al.: Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials. Cancer Treat Rev 30 (4): 359-68, 2004.</Citation><Citation idx="45" PMID="25230595">Slotman BJ, van Tinteren H, Praag JO, et al.: Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 385 (9962): 36-42, 2015.</Citation><Citation idx="46" PMID="17699816">Slotman B, Faivre-Finn C, Kramer G, et al.: Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357 (7): 664-72, 2007.</Citation><Citation idx="47" PMID="17989394">Shivnani AT: Prophylactic cranial irradiation in small-cell lung cancer. N Engl J Med 357 (19): 1977; author reply 1978, 2007.</Citation></ReferenceSection></SummarySection><SummarySection id="_167"><SectMetaData><SpecificDiagnosis ref="CDR0000037831">recurrent small cell lung cancer</SpecificDiagnosis><SectionType>Treatment options for recurrent cancer</SectionType></SectMetaData><Title> Treatment of Recurrent SCLC</Title><SummarySection id="_170"><Title>Treatment Options for Patients With Recurrent SCLC</Title><Para id="_168">Treatment options for patients with recurrent small cell lung cancer (SCLC) include:</Para><OrderedList id="_169" Style="Arabic">
     <ListItem><SummaryRef href="CDR0000062945#_172" url="/types/lung/hp/small-cell-lung-treatment-pdq">Chemotherapy</SummaryRef>.<ItemizedList id="_485498" Style="bullet"><ListItem><SummaryRef href="CDR0000062945#_485464" url="/types/lung/hp/small-cell-lung-treatment-pdq">Topotecan</SummaryRef>. </ListItem><ListItem><SummaryRef href="CDR0000062945#_485467" url="/types/lung/hp/small-cell-lung-treatment-pdq">Lurbinectedin</SummaryRef>. </ListItem><ListItem><SummaryRef href="CDR0000062945#_485471" url="/types/lung/hp/small-cell-lung-treatment-pdq">Other chemotherapy agents</SummaryRef>.</ListItem></ItemizedList></ListItem><ListItem><SummaryRef href="CDR0000062945#_485500" url="/types/lung/hp/small-cell-lung-treatment-pdq">Immunotherapy</SummaryRef>.<ItemizedList id="_485499" Style="bullet"><ListItem><SummaryRef href="CDR0000062945#_485501" url="/types/lung/hp/small-cell-lung-treatment-pdq">Tarlatamab</SummaryRef>.</ListItem></ItemizedList></ListItem><ListItem><SummaryRef href="CDR0000062945#_514" url="/types/lung/hp/small-cell-lung-treatment-pdq">Immune checkpoint modulation</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062945#_182" url="/types/lung/hp/small-cell-lung-treatment-pdq">Palliative therapy</SummaryRef>.</ListItem><ListItem>Phase I and II clinical trials evaluating new drugs, including bispecific T-cell engager (BiTE) immunotherapies.</ListItem></OrderedList><Para id="_171">At the time of recurrence, many patients with SCLC are potential candidates for further therapy.</Para><Para id="_512">For patients with recurrent SCLC, immune checkpoint modulation with anti–programmed death-ligand 1 (anti–PD-L1) antibodies may lead to durable responses either as single agents or in combination with cytotoxic T lymphocyte antigen-4 (anti–CTLA-4). Impacts on long-term survival from these approaches are being assessed in randomized trials. </Para><SummarySection id="_172"><Title>Chemotherapy</Title><Para id="_174">Although second-line chemotherapy has produced tumor regression, responses are usually short lived. The median survival is rarely more than 12 months and usually less than 6 months after second-line therapy.<Reference refidx="1"/> Response to first-line chemotherapy predicts subsequent response to second-line therapy.</Para><Para id="_175">As in other chemosensitive tumors (e.g., Hodgkin lymphoma and ovarian epithelial cancer), two main categories of patients receiving second-line chemotherapy have been described: sensitive and resistant. Sensitive patients have a first-line response that lasted more than 90 days after treatment was completed. These patients have the greatest benefit from second-line chemotherapy. Patients with sensitive disease respond to the same initial regimen in approximately 50% of cases; however, cumulative toxic effects may ensue.<Reference refidx="2"/> Resistant patients either did not respond to first-line chemotherapy or responded initially but relapsed within 90 days of completion of their primary therapy.<Reference refidx="3"/> Results from phase II studies of drugs such as topotecan, irinotecan, and gemcitabine indicate that response rates to agents vary depending on whether patients have sensitive, resistant, or refractory disease.<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/>[<LOERef href="CDR0000810037" dictionary="NotSet" audience="Health professional">Level of evidence C2</LOERef>]</Para><Para id="_245">Topotecan is a standard chemotherapy for recurrent SCLC.<Reference refidx="9"/><Reference refidx="10"/> Lurbinectedin, a selective inhibitor of oncogenic transcription, is another option.<Reference refidx="11"/> Patients with sensitive disease may achieve response to a number of agents including topotecan, irinotecan, taxanes, vinorelbine, paclitaxel, or gemcitabine.<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/>[<LOERef href="CDR0000810037" dictionary="NotSet" audience="Health professional">Level of evidence C2</LOERef>] Response rates for combination agents are generally higher than those reported for single agents,<Reference refidx="15"/><Reference refidx="16"/> and one phase III study reported improved survival for patients with sensitive disease treated with combination cisplatin, etoposide, and irinotecan. However, higher rates of toxicity have been seen.<Reference refidx="17"/></Para><SummarySection id="_485464"><Title>Topotecan</Title><Para id="_485465">Evidence (topotecan and other chemotherapy agents):</Para><OrderedList id="_485466" Style="Arabic"><ListItem>A randomized comparison of second-line treatment with either cyclophosphamide, doxorubicin, and vincristine or topotecan in patients with sensitive disease reported no significant difference in response rates or survival. However, palliation of common lung cancer symptoms was better with topotecan.<Reference refidx="9"/>[<LOERef href="CDR0000810021" dictionary="NotSet" audience="Health professional">Level of evidence A3</LOERef>]</ListItem><ListItem>A phase III trial comparing chemotherapy with best supportive care (BSC) in patients with relapsed SCLC demonstrated that the addition of oral topotecan to BSC significantly increased overall survival (OS) and resulted in better symptom control compared with BSC alone.<Reference refidx="10"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] The study enrolled 141 patients with chemosensitive or chemoresistant relapsed SCLC who were unsuitable for further standard intravenous chemotherapy. The median survivals for patients receiving topotecan plus BSC were 25.9 weeks versus 13.9 weeks for BSC alone (<Emphasis>P</Emphasis> = .01).<Reference refidx="10"/></ListItem><ListItem>A randomized phase III trial (CWRU-SKF-1598 [<ProtocolRef nct_id="NCT00003917">NCT00003917</ProtocolRef>]) of 304 patients assessed the use of oral topotecan (2.3 mg/m<Superscript>2</Superscript>/day for 5 days every 21 days) or intravenous topotecan (1.5 mg/m<Superscript>2</Superscript>/day for 5 days every 21 days). Confirmed response rates were 18.3% and 21.9%, respectively.<Reference refidx="12"/>[<LOERef href="CDR0000810025" dictionary="NotSet" audience="Health professional">Level of evidence B1</LOERef>] Secondary end points of median survival and 1-year survival rates were also similar (33 weeks vs. 35 weeks and 33% vs. 29%, respectively). Patients receiving oral topotecan experienced less grade 4 neutropenia (47% vs. 64.2%) but more diarrhea of all grades (35.9% vs. 19.9%) than with intravenous topotecan. Quality-of-life (QOL) analysis (using a nonvalidated QOL questionnaire) demonstrated no significant difference between the two arms.</ListItem></OrderedList></SummarySection><SummarySection id="_485467"><Title>Lurbinectedin</Title><Para id="_485468">Evidence (lurbinectedin):</Para><OrderedList id="_485469" Style="Arabic"><ListItem>	A single-arm, open-label, phase II basket trial (<ProtocolRef nct_id="NCT02454972">NCT02454972</ProtocolRef>) enrolled 105 patients with SCLC who had been previously treated with one line of a chemotherapy-containing regimen.<Reference refidx="11"/> <ItemizedList id="_485470" Style="bullet"><ListItem>The overall  response rate after treatment with lurbinectedin was 35% (95% confidence interval [CI], 26%−45%), with a median response duration of 5.3 months (95% CI, 4.1−6.4). </ListItem><ListItem>The overall  response rate was 45% (95% CI, 32%−58%) for patients with chemosensitive disease and 22% (95% CI, 11%−37%) for patients with chemoresistant disease. </ListItem><ListItem>The median duration of response was 6.2 months (95% CI, 3.5−7.3) for patients with chemosensitive disease and 4.7 months (95% CI, 2.6−5.6) for patients with chemoresistant disease.<Reference refidx="11"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_485471"><Title>Other chemotherapy agents</Title><Para id="_485472">Evidence (other chemotherapy agents):</Para><OrderedList id="_485473" Style="Arabic"><ListItem>	A phase III trial (University Hospital Medical Information Network Clinical Trials Registry [UMIN000000828]) in Japan included 180 patients with extensive-stage SCLC, who had responded to first-line platinum-doublet chemotherapy but had their disease progress more than 90 days after completion of chemotherapy. Patients were randomly assigned  1:1 to receive intravenous topotecan for four cycles, which is the standard of care, or five 2-week cycles of cisplatin, etoposide, and irinotecan.<Reference refidx="17"/><ItemizedList id="_485474" Style="bullet"><ListItem>The primary end point of OS was significantly prolonged with the combination of cisplatin, etoposide, and  irinotecan (18.2 months; 95% CI, 15.7–20.6) compared with topotecan alone (12.5 months; 95% CI, 10.8–14.9; hazard ratio, 0.67; 90% CI, 0.51–0.88; <Emphasis>P</Emphasis> = .0079). </ListItem><ListItem>Rates of grade 3 to 4 toxicities were higher in patients treated with the combination regimen. Toxicities included febrile neutropenia (31% for the combination arm vs. 7% for topotecan alone) and thrombocytopenia (41% for the combination arm vs. 28% for topotecan alone).<Reference refidx="17"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</ListItem></ItemizedList></ListItem></OrderedList></SummarySection></SummarySection><SummarySection id="_485500"><Title>Immunotherapy</Title><SummarySection id="_485501"><Title>Tarlatamab</Title><Para id="_485502">Tarlatamab is a BiTE immunotherapy drug that targets delta-like ligand 3 (DLL3) and CD3. BiTE technology is a targeted immuno-oncology platform designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer.</Para><Para id="_485503">Evidence (tarlatamab):</Para><OrderedList id="_485504" Style="Arabic"><ListItem>The  phase II <ProtocolRef nct_id="NCT05060016">DeLLphi-301</ProtocolRef> trial (NCT05060016) evaluated the efficacy and safety of two doses of tarlatamab (10 mg or 100 mg every 2 weeks) in 220 patients with previously treated SCLC.  Patients had previously received a median of two lines of treatment.	The primary end point was objective response rate by blinded independent central review.<Reference refidx="18"/><ItemizedList id="_485505" Style="bullet"><ListItem>	The objective response rates were 40% (97.5% CI, 29%–52%) for patients who received 10 mg of tarlatamab and 32% (97.5% CI, 21%–44%) for patients who received 100 mg of tarlatamab. The median duration of response was not reached.</ListItem><ListItem>	The median progression-free survival was 4.9 months (95% CI, 2.9–6.7) with 10 mg of tarlatamab and 3.9 months (95% CI, 2.6–4.4) with 100 mg of tarlatamab. </ListItem><ListItem>	The most common adverse events were cytokine release syndrome (51% with 10 mg, 61% with 100 mg), decreased appetite, pyrexia, constipation, and anemia.</ListItem><ListItem>	Cytokine release syndrome occurred after the first one to two doses and was managed with supportive care. </ListItem><ListItem>	Neurological adverse events suggestive of immune effector cell–associated neurotoxicity syndrome were higher for patients who received 100 mg (28%) compared with patients who received 10 mg (8%).</ListItem><ListItem>The 10-mg dose showed improved tolerability over the 100-mg dose, with similar efficacy.</ListItem></ItemizedList></ListItem></OrderedList></SummarySection></SummarySection><SummarySection id="_514"><Title>Immune checkpoint modulation</Title><Para id="_485485">Early phase Ib and II trials showed objective response rates of 10% to 33% with nivolumab or pembrolizumab treatment in patients with disease progression after one or more lines of chemotherapy, resulting in accelerated approval from the U.S. Food and Drug Administration. However, both agents were voluntarily withdrawn after subsequent trials failed to confirm benefit.<Reference refidx="19"/><Reference refidx="20"/>  </Para></SummarySection><SummarySection id="_182"><Title>Palliative therapy</Title><Para id="_181">Patients with central nervous system (CNS) recurrences can often obtain palliation of symptoms with additional chemotherapy and/or radiation therapy. A retrospective review showed that 43% of patients had disease response when treated with additional chemotherapy at the time of CNS relapse.<Reference refidx="21"/> Most patients treated with radiation therapy obtain objective responses and improvement after radiation therapy.<Reference refidx="22"/></Para><Para id="_231">Some patients with intrinsic endobronchial obstructing lesions or extrinsic compression caused by the tumor have achieved successful palliation with endobronchial laser therapy (for endobronchial lesions only) and/or brachytherapy.<Reference refidx="23"/> Expandable metal stents can be safely inserted under local anesthesia via the bronchoscope, which results in improved symptoms and pulmonary function in patients with malignant airways obstruction.<Reference refidx="24"/></Para><Para id="_183"> Patients with progressive intrathoracic tumor after failing initial chemotherapy can achieve significant tumor responses, palliation of symptoms, and short-term local control with external-beam radiation therapy. Only the rare patient, however, will experience long-term survival after receiving salvage radiation therapy.<Reference refidx="25"/></Para></SummarySection></SummarySection><SummarySection id="_TrialSearch_167_sid_7"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_167_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="15094178">Davies AM, Evans WK, Mackay JA, et al.: Treatment of recurrent small cell lung cancer. Hematol Oncol Clin North Am 18 (2): 387-416, 2004.</Citation><Citation idx="2" PMID="2824211" MedlineID="88055242">Postmus PE, Berendsen HH, van Zandwijk N, et al.: Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 23 (9): 1409-11, 1987.</Citation><Citation idx="3" PMID="2842464">Giaccone G, Donadio M, Bonardi G, et al.: Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 6 (8): 1264-70, 1988.</Citation><Citation idx="4" PMID="11221015">Sandler AB: Irinotecan in small-cell lung cancer: the US experience. Oncology (Williston Park) 15 (1 Suppl 1): 11-2, 2001.</Citation><Citation idx="5" PMID="11398892">van der Lee I, Smit EF, van Putten JW, et al.: Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 12 (4): 557-61, 2001.</Citation><Citation idx="6" PMID="1321891">Masuda N, Fukuoka M, Kusunoki Y, et al.: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10 (8): 1225-9, 1992.</Citation><Citation idx="7" PMID="8874340">Perez-Soler R, Glisson BS, Lee JS, et al.: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14 (10): 2785-90, 1996.</Citation><Citation idx="8" PMID="12697880" MedlineID="22583965">Masters GA, Declerck L, Blanke C, et al.: Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 21 (8): 1550-5, 2003.</Citation><Citation idx="9" PMID="10080612" MedlineID="99178697">von Pawel J, Schiller JH, Shepherd FA, et al.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (2): 658-67, 1999.</Citation><Citation idx="10" PMID="17135646">O'Brien ME, Ciuleanu TE, Tsekov H, et al.: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24 (34): 5441-7, 2006.</Citation><Citation idx="11" PMID="32224306">Trigo J, Subbiah V, Besse B, et al.: Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 21 (5): 645-654, 2020.</Citation><Citation idx="12" PMID="17513814">Eckardt JR, von Pawel J, Pujol JL, et al.: Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25 (15): 2086-92, 2007.</Citation><Citation idx="13" PMID="9164222" MedlineID="97307007">Ardizzoni A, Hansen H, Dombernowsky P, et al.: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15 (5): 2090-6, 1997.</Citation><Citation idx="14" PMID="8604245">Furuse K, Kubota K, Kawahara M, et al.: Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology 53 (2): 169-72, 1996 Mar-Apr.</Citation><Citation idx="15" PMID="9461009" MedlineID="98120907">Smit EF, Fokkema E, Biesma B, et al.: A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77 (2): 347-51, 1998.</Citation><Citation idx="16" PMID="17065590">Rocha-Lima CM, Herndon JE, Lee ME, et al.: Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol 18 (2): 331-7, 2007.</Citation><Citation idx="17" PMID="27312053">Goto K, Ohe Y, Shibata T, et al.: Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 17 (8): 1147-1157, 2016.</Citation><Citation idx="18" PMID="37861218">Ahn MJ, Cho BC, Felip E, et al.: Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med 389 (22): 2063-2075, 2023.</Citation><Citation idx="19" PMID="27269741">Antonia SJ, López-Martin JA, Bendell J, et al.: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17 (7): 883-895, 2016.</Citation><Citation idx="20" PMID="28813164">Ott PA, Elez E, Hiret S, et al.: Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol 35 (34): 3823-3829, 2017.</Citation><Citation idx="21" PMID="1325541" MedlineID="92388971">Kristensen CA, Kristjansen PE, Hansen HH: Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J Clin Oncol 10 (9): 1498-502, 1992.</Citation><Citation idx="22" PMID="2830211" MedlineID="88138903">Carmichael J, Crane JM, Bunn PA, et al.: Results of therapeutic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys 14 (3): 455-9, 1988.</Citation><Citation idx="23" PMID="1696452" MedlineID="90343494">Miller JI, Phillips TW: Neodymium:YAG laser and brachytherapy in the management of inoperable bronchogenic carcinoma. Ann Thorac Surg 50 (2): 190-5; discussion 195-6, 1990.</Citation><Citation idx="24" PMID="8779125" MedlineID="96246521">Wilson GE, Walshaw MJ, Hind CR: Treatment of large airway obstruction in lung cancer using expandable metal stents inserted under direct vision via the fibreoptic bronchoscope. Thorax 51 (3): 248-52, 1996.</Citation><Citation idx="25" PMID="6197165" MedlineID="84081932">Ochs JJ, Tester WJ, Cohen MH, et al.: "Salvage" radiation therapy for intrathoracic small cell carcinoma of the lung progressing on combination chemotherapy. Cancer Treat Rep 67 (12): 1123-6, 1983.</Citation></ReferenceSection></SummarySection><SummarySection id="_188"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (05/14/2025)</Title><Para id="_279">The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.</Para><Para id="_485524">Editorial changes were made to this summary.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062945#_AboutThis_1" url="/types/lung/hp/small-cell-lung-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of small cell lung cancer. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Small Cell Lung Cancer Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Janet Dancey, MD, FRCPC (Ontario Institute for Cancer Research &amp; NCIC Clinical Trials Group)</ListItem><ListItem>Monaliben Patel, MD (University of Rochester Medical Center)</ListItem><ListItem>Arun Rajan, MD (National Cancer Institute)</ListItem><ListItem>Eva Szabo, MD (National Cancer Institute)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Adult Treatment Editorial Board. PDQ Small Cell Lung Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq">https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389347]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateLastModified>2025-05-14</DateLastModified></Summary>
